1
|
Huang L, Cheng S, Liu Z, Zou C, Yan H. [Transdermal patches containing Cassia seed extract applied at the navel for slow transit constipation in rats: therapeutic effect and analysis of the spectrum-effect relationship]. Nan Fang Yi Ke Da Xue Xue Bao 2024; 44:720-726. [PMID: 38708506 DOI: 10.12122/j.issn.1673-4254.2024.04.14] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/07/2024]
Abstract
OBJECTIVE To explore the therapeutic effect of transdermal patches containing Cassia seed extract applied at the navel on slow transit constipation (STC) in rats and explore the spectrum-effect relationship of the patches. METHOD In a STC rat model established by gavage of compound diphenoxylate suspension for 14 days, the transdermal patches containing low, medium and high doses of Cassia seed extract (41.75, 125.25, and 375.75 mg/kg, respectively) were applied at the Shenque acupoint on the abdomen for 14 days after modeling, with constipation patches (13.33 mg/kg) as the positive control. After the treatment, fecal water content and intestinal propulsion rate of the rats were calculated, the pathological changes in the colon were observed with HE staining. Serum NO and NOS levels and the total protein content and NO, NOS and AChE expressions in the colon tissue were determined. HPLC fingerprints of the transdermal patches were established, and the spectrum-effect relationship between the common peaks of the patches and its therapeutic effect were analyzed. RESULTS Treatment with the transdermal patches containing Cassia seed extract significantly increased fecal water content and intestinal propulsion rate of the rat models, where no pathological changes in the colon tissue were detected. The treatment also suppressed the elevations of serum and colonic NO and NOS levels and reduction of AChE in STC rats. Twenty-eight common peaks were confirmed in the HPLC fingerprints of 6 batches of Cassia seed extract-containing patches. Analysis of the spectrum-effect relationship showed that autrantio-obtusin had the greatest contribution to the therapeutic effect of the patches in STC rats. CONCLUSION The Cassia seed extract-containing patches alleviates STC in rats via synergistic actions of multiple active ingredients in the extract, where autrantio-obtusin, rhein, chrysoobtusin, obtusin, obtusifolin, emodin, chrysophanol, and physcion are identified as the main active ingredients.
Collapse
Affiliation(s)
- L Huang
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| | - S Cheng
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| | - Z Liu
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| | - C Zou
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| | - H Yan
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| |
Collapse
|
2
|
Shi LP, Zou C, Mao LJ, Chen TT, Xie T. The expression of UNC5D is abnormal in the early stage of colorectal tumors associated with its proliferation and migration. Eur Rev Med Pharmacol Sci 2024; 28:199-213. [PMID: 38235871 DOI: 10.26355/eurrev_202401_34905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2024]
Abstract
OBJECTIVE Colorectal adenomas are an important precancerous lesion of colorectal adenoma with a high incidence. This study aims to explore new prognostic targets for colorectal adenomas through bioinformatics techniques. MATERIALS AND METHODS In this study, data from 29 colonic adenomas and 38 normal colonic mucosa in GSE37364 were analyzed to screen for differentially expressed genes (DEGs). Then, batch survival analysis, construction of risk model, mutation analysis, Cox regression analysis and expression analysis were performed on DEGs to determine the hub genes of this study. Finally, immune correlation analysis and cell experiments were carried out on the hub gene to explore its potential mechanism. RESULTS In our study, a total of 431 up-regulated and 809 down-regulated differentially expressed genes (DEGs) were identified. Among these, Unc-5 Netrin Receptor D (UNC5D) emerged as a pivotal gene associated with colorectal adenoma. Notably, UNC5D expression levels were found to be significantly higher in normal tissues compared to colorectal adenoma tissues. Furthermore, our analysis demonstrated that UNC5D showed promising diagnostic potential for patients with colon adenocarcinoma. In vitro experiments revealed that the overexpression of UNC5D had a profound impact on the behavior of colorectal tumor cells. Specifically, it led to a substantial reduction in the proliferation, motility, and invasion of these tumor cells. Additionally, UNC5D was shown to exert control over STAT1/STAT3 phosphorylation, which in turn regulated the expression of PD-L1 in response to interferon (IFN) stimulation. These findings highlight the significant role of UNC5D in modulating immune responses and the development of colorectal adenoma. UNC5D emerges as a potential diagnostic biomarker and an attractive immunotherapeutic target in the context of colorectal malignancies. These results call for further exploration of UNC5D-based strategies for the diagnosis and treatment of colorectal adenoma and adenocarcinoma. CONCLUSIONS In addition to having the potential to be used as a diagnostic biomarker and an immunotherapeutic target in colorectal malignancies, UNC5D is necessary for the growth of colorectal adenomas. Additionally, UNC5D controlled STAT1/STAT3 phosphorylation to suppress the growth of colorectal cancers by regulating IFN-induced PD-L1 expression.
Collapse
Affiliation(s)
- L-P Shi
- Good Clinical Practice Center, The Affiliated Hospital of Nanjing University of Chinese Medicine, Qinhuai District, Nanjing, Jiangsu, China.
| | | | | | | | | |
Collapse
|
3
|
Liu SJ, Pak J, Zou C, Payne E, Foster K, Vasudevan H, Casey-Clyde T, Seo K, O'Loughlin T, Wu D, Lim D, Ozawa T, de Groot J, Berger MS, Weiss W, Gilbert LA, Raleigh D. Identifying Gene-Treatment Interactions and Targetable Radiation Vulnerabilities in Glioblastoma through Coupling of In Vivo CRISPR Perturbation and Single Cell Transcriptomics. Int J Radiat Oncol Biol Phys 2023; 117:S102. [PMID: 37784271 DOI: 10.1016/j.ijrobp.2023.06.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Glioblastoma (GBM) is an incurable brain tumor comprised of dynamic malignant cell states and microenvironment components that underlie treatment resistance. Here we use genome-wide CRISPR/Cas9 functional genomics to define biological drivers and therapeutic vulnerabilities across human and mouse GBM models. To interrogate these mechanisms in the context of the tumor microenvironment and in vivo physiology, we established in vivo Perturb-seq intracranially, a technique coupling functional genomics with single cell transcriptomics, where each cell is an individual experiment. MATERIALS/METHODS Orthotopic intracranial tumor models were established using human (GBM6, GBM43) or mouse (GL261, SB28) GBM cells stably expressing CRISPR interference (CRISPRi) machinery. Perturb-seq target selection for phenotyping of gene-treatment interactions was performed using genome-wide CRISPRi screens ± radiotherapy in cell cultures. Dual sgRNA lentivirus libraries were transduced either ex vivo prior to intracranial GBM cell transplantation or in vivo using intratumor convection enhanced delivery (CED). Transcriptional phenotyping was performed using single-cell RNA-seq with CRISPR direct capture following focal brain radiotherapy (2 Gy x 5) or mock treatment. GBM cell states were validated using single-nucleus RNA-seq data from 86 primary-recurrent patient-matched GBMs. Mechanistic and functional validation was performed using small molecule inhibitors, immunohistochemistry, clonogenic assays, and in vivo survival experiments. RESULTS In vivo Perturb-seq ± radiotherapy of 48 genes underlying GBM radiotherapy responses, which were enriched for DNA damage response and metabolic pathways, was performed in > 425,000 single cells. Radiotherapy induced 16 distinct GBM cell states, and genetic perturbations reprogrammed these cell states in a treatment-dependent fashion. Quantitative modeling of gene/radiotherapy interactions using high dimensional manifolds revealed in vivo-specific genetic dependencies. We revealed a critical role for Prkdc, the catalytic subunit of DNA-dependent protein kinase (DNA-PK), as a radiotherapy sensitizer through regulation of cell intrinsic growth and oxidative stress pathways, and cell extrinsic interferon and signaling pathways that altered cell-cell interactions in vivo. These pathways were also disrupted in single-nucleus RNA-seq analysis of post-radiotherapy human GBM tumors. Inhibition of Prkdc using a Food and Drug Administration approved small molecule sensitized GBM cells to radiotherapy and extended survival in mice harboring human intracranial xenografts. CONCLUSION We establish in vivo Perturb-seq in orthotopic GBM models as a platform for simultaneous functional genomic discovery and characterization of therapeutic targets, revealing an underappreciated role for Prkdc in GBM tumors in vivo that is targetable using small molecules. These tools are adaptable for a wide range of disease models and treatment modalities.
Collapse
Affiliation(s)
- S J Liu
- University of California San Francisco, Department of Radiation Oncology, San Francisco, CA
| | - J Pak
- University of California, San Francisco, San Francisco, CA
| | - C Zou
- University of California, San Francisco, San Francisco, CA
| | - E Payne
- University of California, San Francisco, San Francisco, CA
| | - K Foster
- University of California, San Francisco, San Francisco, CA
| | - H Vasudevan
- University of California, San Francisco, Department of Radiation Oncology, San Francisco, CA
| | - T Casey-Clyde
- University of California, San Francisco, San Francisco, CA
| | - K Seo
- University of California San Francisco, SAN FRANCISCO, CA
| | - T O'Loughlin
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - D Wu
- University of California, San Francisco, San Francisco, CA
| | - D Lim
- University of California San Francisco, San Francisco, CA
| | - T Ozawa
- University of California, San Francisco, San Francisco, CA
| | - J de Groot
- University of California, San Francisco, San Francisco, CA
| | - M S Berger
- University of California San Francisco, Department of Neurological Surgery, San Francisco, CA
| | - W Weiss
- University of California, San Francisco, San Francisco, CA
| | - L A Gilbert
- University of California, San Francisco, San Francisco, CA
| | - D Raleigh
- University of California San Francisco, Department of Radiation Oncology, San Francisco, CA
| |
Collapse
|
4
|
Yu C, Hu XY, Zou C, Yu FF, Liu B, Li Y, Liu Y, Song LJ, Tan L, Li Q, Hu YC, He HY, Chen MY, Zou Z. Associations between severe pulmonary function and residual CT abnormalities in rehabilitating COVID-19 patients. Eur Rev Med Pharmacol Sci 2021; 25:7585-7597. [PMID: 34919259 DOI: 10.26355/eurrev_202112_27457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Coronavirus disease 2019 (COVID-19) spread around the world in 2020. Abnormal pulmonary function and residual CT abnormalities were observed in COVID-19 patients during recovery. Appropriate rehabilitation training is around the corner. The correlation between spirometric impairment and residual CT abnormality remains largely unknown. PATIENTS AND METHODS A cross-sectional study conducted on the pulmonary function of 101 convalescent COVID-19 patients before discharge. Multivariate analysis was used to establish a scoring system to evaluate the spirometric abnormality based on residual chest CT. RESULTS Lung consolidation area >25% and severe-type COVID-19 were two independent risk factors for severe pulmonary dysfunction. Besides, a scoring system was established. People scoring more than 12 points have more chances (17 times) to get severe pulmonary function impairment before discharge. CONCLUSIONS For the first time, a chest CT characteristics-based grading system was suggested to predict the pulmonary dysfunction of COVID-19 patients during convalescence in this study. This study may provide suggestions for pulmonary rehabilitation.
Collapse
Affiliation(s)
- C Yu
- Department of Respiratory and Critical Care Medicine, Naval Hospital of Eastern Theater of PLA, Zhoushan, Zhejiang Province, P.R. China.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
5
|
Li L, Zou C, Dong S, Wu ZX, Ashby CR, Chen ZS, Qiu C. Lurbinectedin for the treatment of small cell lung cancer. Drugs Today (Barc) 2021; 57:377-385. [PMID: 34151904 DOI: 10.1358/dot.2021.57.6.3294559] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Small cell lung cancer (SCLC) is a rapidly progressive, aggressive metastatic and lethal subtype of lung cancer. Unfortunately, there has been little progress regarding the development of novel treatments for SCLC. However, lurbinectedin, a transcriptional inhibitor, has emerged as a potential novel treatment for cancer. It produces antitumor efficacy by inhibiting oncogenic transcription activity, inducing the accumulation of DNA double-strand breaks and modulating the tumor microenvironment (TME). Data from phase I/II trials indicates that lurbinectedin has significant antitumor efficacy and tolerable adverse effects in SCLC patients. Furthermore, lurbinectedin is efficacious in platinum-sensitive and platinum-resistant SCLC patients and in those with SCLC relapse after second-line treatment. In 2020, the U.S. Food and Drug Administration (FDA) approved lurbinectedin for the treatment of adult patients with metastatic SCLC or for patients that have received platinum-based chemotherapy. In this review, we discuss the molecular profile and the preclinical and clinical studies of lurbinectedin in the treatment of SCLC patients.
Collapse
Affiliation(s)
- L Li
- Key Laboratory of Shenzhen Respiratory Diseases, Institute of Respiratory Disease, The Second Affiliated Hospital of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, China
| | - C Zou
- Clinical Research Center, The Second Affiliated Hospital of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, China
| | - S Dong
- Clinical Research Center, The Second Affiliated Hospital of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, China
| | - Z-X Wu
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA
| | - C R Ashby
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA
| | - Z-S Chen
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA.
| | - C Qiu
- Key Laboratory of Shenzhen Respiratory Diseases, Institute of Respiratory Disease, The Second Affiliated Hospital of Jinan University, The First Affiliated Hospital of Southern University of Science and Technology, Shenzhen People's Hospital, Shenzhen, China.
| |
Collapse
|
6
|
Abstract
Non-small cell lung cancer (NSCLC) is one of the most devastating cancers with high mortality worldwide. By inhibiting the activity of specific molecular targets in the cancer cells, tyrosine kinase inhibitors (TKIs) have become a standard treatment in combating NSCLC. Tepotinib hydrochloride is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. Tepotinib demonstrated durable clinical response in phase II clinical trials, which led to its approval for use in Japan and breakthrough therapy designation and accelerated approval in the U.S. These progresses highlighted tepotinib as a promising candidate for NSCLC patients. This review summarizes the pharmacological profile of tepotinib, preclinical studies and landmark clinical trials of tepotinib. In addition, we share our perspectives on the future direction of tepotinib as a novel anticancer drug.
Collapse
Affiliation(s)
- Z-X Wu
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA
| | - J Li
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA and Department of Otolaryngology-Head and Neck Surgery, Zhongnan Hospital of Wuhan University, Wuhan, China
| | - S Dong
- Key Laboratory of Medical Electrophysiology of Education Ministry, School of Pharmacy, Southwest Medical University, China and Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen, Guangdong, China
| | - L Lin
- Cell Research Center, Shenzhen Bolun Institute of Biotechnology, Shenzhen, China
| | - C Zou
- Key Laboratory of Medical Electrophysiology of Education Ministry, School of Pharmacy, Southwest Medical University, China and Shenzhen Public Service Platform on Tumor Precision Medicine and Molecular Diagnosis, Southern University of Science and Technology, Shenzhen, Guangdong, China. zouchang.cuhk@gmail
| | - Z-S Chen
- Department of Pharmaceutical Sciences, College of Pharmacy and Health Sciences, St. John's University, Queens, New York, USA.
| |
Collapse
|
7
|
Yan H, Zou C. [Use of Trichosanthis fructus and the core drug pair Trichosanthis fructus- Glycyrrhizae radix et rhizoma in traditional Chinese prescriptions: molecular mechanisms in network pharmacology and molecular docking]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41:173-183. [PMID: 33624589 DOI: 10.12122/j.issn.1673-4254.2021.02.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To analyze the rationale for use of Trichosanthis fructus in traditional Chinese prescriptions and explore the molecular mechanism of the core drug pair Trichosanthis fructus-Glycyrrhizae radix et rhizoma for treatment of phlegm syndrome diseases. OBJECTIVE We analyzed the cumulative frequency of the use of Trichosanthis fructus in traditional Chinese prescriptions and the disease spectrum treated using the prescriptions containing Trichosanthis fructus. We searched TCMSP database for the chemical components of Trichosanthis fructus and Glycyrrhizae radix et rhizoma and explored their target proteins using Swiss Target Prediction database. We also searched the CooLGeN and GeneCards databases for the potential disease target proteins using the key words "phlegm syndrome". The chemical component-target protein-signal pathway network was constructed using DAVID database to analyze the molecular mechanism of Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair for treatment of phlegm syndrome diseases, and the result was verified by molecular docking technology. OBJECTIVE A total of 1700 prescriptions containing Trichosanthis fructus were retrieved, which were used for treatment of 28 diseases. Phlegm syndrome was the most frequent among the 28 diseases (14.0%). The Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair had a cumulative frequency of 113 for use in treatment of phlegm diseases, and was the core drug pair in prescriptions containing Trichosanthis fructus. Fifty-two chemical components related to phlegm syndrome diseases were identified in the drug pair (9 in Trichosanthis fructus and 43 in Glycyrrhizae radix et rhizoma), and their therapeutic effects were mediated by a total of 41 target proteins involving the cancer pathway, NOD-like receptor signaling pathway and another 17 signal pathways. The results of molecular docking showed that 40 chemical components docking with 10 target protein molecules had total scores greater than 5. OBJECTIVE The different formulations of Trichosanthis fructus containing prescriptions serve different therapeutic purposes. The mechanisms of the Trichosanthis fructus-Glycyrrhizae radix et rhizoma drug pair for treatment of phlegm syndrome diseases involve multiple pathways for regulating cell proliferation, apoptosis and other biological processes.
Collapse
Affiliation(s)
- H Yan
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| | - C Zou
- School of Pharmacy, Wannan Medical College, Wuhu 241002, China
| |
Collapse
|
8
|
Demina EP, Smutova V, Pan X, Fougerat A, Guo T, Zou C, Chakraberty R, Snarr BD, Shiao TC, Roy R, Orekhov AN, Miyagi T, Laffargue M, Sheppard DC, Cairo CW, Pshezhetsky AV. Neuraminidases 1 and 3 Trigger Atherosclerosis by Desialylating Low-Density Lipoproteins and Increasing Their Uptake by Macrophages. J Am Heart Assoc 2021; 10:e018756. [PMID: 33554615 PMCID: PMC7955353 DOI: 10.1161/jaha.120.018756] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Background Chronic vascular disease atherosclerosis starts with an uptake of atherogenic modified low-density lipoproteins (LDLs) by resident macrophages, resulting in formation of arterial fatty streaks and eventually atheromatous plaques. Increased plasma sialic acid levels, increased neuraminidase activity, and reduced sialic acid LDL content have been previously associated with atherosclerosis and coronary artery disease in human patients, but the mechanism underlying this association has not been explored. Methods and Results We tested the hypothesis that neuraminidases contribute to development of atherosclerosis by removing sialic acid residues from glycan chains of the LDL glycoprotein and glycolipids. Atherosclerosis progression was investigated in apolipoprotein E and LDL receptor knockout mice with genetic deficiency of neuraminidases 1, 3, and 4 or those treated with specific neuraminidase inhibitors. We show that desialylation of the LDL glycoprotein, apolipoprotein B 100, by human neuraminidases 1 and 3 increases the uptake of human LDL by human cultured macrophages and by macrophages in aortic root lesions in Apoe-/- mice via asialoglycoprotein receptor 1. Genetic inactivation or pharmacological inhibition of neuraminidases 1 and 3 significantly delays formation of fatty streaks in the aortic root without affecting the plasma cholesterol and LDL levels in Apoe-/- and Ldlr-/- mouse models of atherosclerosis. Conclusions Together, our results suggest that neuraminidases 1 and 3 trigger the initial phase of atherosclerosis and formation of aortic fatty streaks by desialylating LDL and increasing their uptake by resident macrophages.
Collapse
Affiliation(s)
- Ekaterina P Demina
- Departments of Pediatrics and Biochemistry Sainte-Justine University Hospital Research CenterUniversity of Montreal Quebec Canada
| | - Victoria Smutova
- Departments of Pediatrics and Biochemistry Sainte-Justine University Hospital Research CenterUniversity of Montreal Quebec Canada
| | - Xuefang Pan
- Departments of Pediatrics and Biochemistry Sainte-Justine University Hospital Research CenterUniversity of Montreal Quebec Canada
| | - Anne Fougerat
- Departments of Pediatrics and Biochemistry Sainte-Justine University Hospital Research CenterUniversity of Montreal Quebec Canada
| | - Tianlin Guo
- Department of Chemistry University of Alberta Edmonton Alberta Canada
| | - Chunxia Zou
- Department of Chemistry University of Alberta Edmonton Alberta Canada
| | | | - Brendan D Snarr
- Departments of Medicine, Microbiology and Immunology McGill University Montreal Quebec Canada
| | - Tze C Shiao
- Department of Chemistry Université du Québec à Montréal Montreal Quebec Canada
| | - Rene Roy
- Department of Chemistry Université du Québec à Montréal Montreal Quebec Canada
| | | | - Taeko Miyagi
- Miyagi Cancer Center Research Institute Natori Miyagi Japan
| | - Muriel Laffargue
- Institut National de la Santé et de la Recherche MédicaleUMR 1048Institute of Metabolic and Cardiovascular Diseases Toulouse France
| | - Donald C Sheppard
- Departments of Medicine, Microbiology and Immunology McGill University Montreal Quebec Canada
| | | | - Alexey V Pshezhetsky
- Departments of Pediatrics and Biochemistry Sainte-Justine University Hospital Research CenterUniversity of Montreal Quebec Canada
| |
Collapse
|
9
|
De Leoz MLA, Duewer DL, Fung A, Liu L, Yau HK, Potter O, Staples GO, Furuki K, Frenkel R, Hu Y, Sosic Z, Zhang P, Altmann F, Grunwald-Grube C, Shao C, Zaia J, Evers W, Pengelley S, Suckau D, Wiechmann A, Resemann A, Jabs W, Beck A, Froehlich JW, Huang C, Li Y, Liu Y, Sun S, Wang Y, Seo Y, An HJ, Reichardt NC, Ruiz JE, Archer-Hartmann S, Azadi P, Bell L, Lakos Z, An Y, Cipollo JF, Pucic-Bakovic M, Štambuk J, Lauc G, Li X, Wang PG, Bock A, Hennig R, Rapp E, Creskey M, Cyr TD, Nakano M, Sugiyama T, Leung PKA, Link-Lenczowski P, Jaworek J, Yang S, Zhang H, Kelly T, Klapoetke S, Cao R, Kim JY, Lee HK, Lee JY, Yoo JS, Kim SR, Suh SK, de Haan N, Falck D, Lageveen-Kammeijer GSM, Wuhrer M, Emery RJ, Kozak RP, Liew LP, Royle L, Urbanowicz PA, Packer NH, Song X, Everest-Dass A, Lattová E, Cajic S, Alagesan K, Kolarich D, Kasali T, Lindo V, Chen Y, Goswami K, Gau B, Amunugama R, Jones R, Stroop CJM, Kato K, Yagi H, Kondo S, Yuen CT, Harazono A, Shi X, Magnelli PE, Kasper BT, Mahal L, Harvey DJ, O'Flaherty R, Rudd PM, Saldova R, Hecht ES, Muddiman DC, Kang J, Bhoskar P, Menard D, Saati A, Merle C, Mast S, Tep S, Truong J, Nishikaze T, Sekiya S, Shafer A, Funaoka S, Toyoda M, de Vreugd P, Caron C, Pradhan P, Tan NC, Mechref Y, Patil S, Rohrer JS, Chakrabarti R, Dadke D, Lahori M, Zou C, Cairo C, Reiz B, Whittal RM, Lebrilla CB, Wu L, Guttman A, Szigeti M, Kremkow BG, Lee KH, Sihlbom C, Adamczyk B, Jin C, Karlsson NG, Örnros J, Larson G, Nilsson J, Meyer B, Wiegandt A, Komatsu E, Perreault H, Bodnar ED, Said N, Francois YN, Leize-Wagner E, Maier S, Zeck A, Heck AJR, Yang Y, Haselberg R, Yu YQ, Alley W, Leone JW, Yuan H, Stein SE. NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods. Mol Cell Proteomics 2020; 19:11-30. [PMID: 31591262 PMCID: PMC6944243 DOI: 10.1074/mcp.ra119.001677] [Citation(s) in RCA: 67] [Impact Index Per Article: 16.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2019] [Revised: 08/26/2019] [Indexed: 01/24/2023] Open
Abstract
Glycosylation is a topic of intense current interest in the development of biopharmaceuticals because it is related to drug safety and efficacy. This work describes results of an interlaboratory study on the glycosylation of the Primary Sample (PS) of NISTmAb, a monoclonal antibody reference material. Seventy-six laboratories from industry, university, research, government, and hospital sectors in Europe, North America, Asia, and Australia submitted a total of 103 reports on glycan distributions. The principal objective of this study was to report and compare results for the full range of analytical methods presently used in the glycosylation analysis of mAbs. Therefore, participation was unrestricted, with laboratories choosing their own measurement techniques. Protein glycosylation was determined in various ways, including at the level of intact mAb, protein fragments, glycopeptides, or released glycans, using a wide variety of methods for derivatization, separation, identification, and quantification. Consequently, the diversity of results was enormous, with the number of glycan compositions identified by each laboratory ranging from 4 to 48. In total, one hundred sixteen glycan compositions were reported, of which 57 compositions could be assigned consensus abundance values. These consensus medians provide community-derived values for NISTmAb PS. Agreement with the consensus medians did not depend on the specific method or laboratory type. The study provides a view of the current state-of-the-art for biologic glycosylation measurement and suggests a clear need for harmonization of glycosylation analysis methods.
Collapse
Affiliation(s)
- Maria Lorna A De Leoz
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899.
| | - David L Duewer
- Chemical Sciences Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| | - Adam Fung
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Lily Liu
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Hoi Kei Yau
- Analytical Development, Agensys, Inc., 1800 Steward Street Santa Monica, California 90404
| | - Oscar Potter
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Gregory O Staples
- Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Kenichiro Furuki
- Astellas Pharma, 5-2-3 Tokodai, Tsukiba, Ibaraki, 300-2698, Japan
| | - Ruth Frenkel
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Yunli Hu
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Zoran Sosic
- Analytical Development, Biogen, 14 Cambridge Center Cambridge, Massachusetts 02142
| | - Peiqing Zhang
- Bioprocessing Technology Institute, 20 Biopolis Way, Level 3 Singapore 138668
| | - Friedrich Altmann
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Clemens Grunwald-Grube
- Department of Chemistry, University of Natural Resources and Life Science, Vienna (BOKU), Muthgasse 18 1190 Wien, Austria
| | - Chun Shao
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Joseph Zaia
- Center for Biomedical Mass Spectrometry, Boston University School of Medicine, 670 Albany Street Boston, Massachusetts 02118
| | - Waltraud Evers
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | | | - Detlev Suckau
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Wiechmann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Anja Resemann
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany
| | - Wolfgang Jabs
- Bruker Daltonik GmbH, Fahrenheitstr. 4, 28359 Bremen, Germany; Department of Life Sciences & Technology, Beuth Hochschule für Technik Berlin, Seestraβe 64, 13347 Berlin, Germany
| | - Alain Beck
- Centre d'Immunologie Pierre Fabre, 5 Avenue Napoléon III, BP 60497, 74164 St Julien-en-Genevois, France
| | - John W Froehlich
- Department of Urology, Boston Children's Hospital, 300 Longwood Avenue Boston Massachusetts 02115
| | - Chuncui Huang
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yan Li
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaming Liu
- Institute of Biophysics, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Shiwei Sun
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Yaojun Wang
- Key Lab of Intelligent Information Processing, Institute of Computing Technology, Chinese Academy of Sciences, 15 Da Tun Road, Chaoyang District, Beijing 100101 China
| | - Youngsuk Seo
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | - Hyun Joo An
- Graduate School of Analytical Science and Technology, Chungnam National University, Gung-dong 220, Yuseong-Gu, Daejeon 305-764, Korea (South)
| | | | | | - Stephanie Archer-Hartmann
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Parastoo Azadi
- Analytical Services, Complex Carbohydrate Research Center, University of Georgia, 315 Riverbend Road Athens, Georgia 30602
| | - Len Bell
- BioCMC Solutions (Large Molecules), Covance Laboratories Limited, Otley Road, Harrogate, North Yorks HG3 1PY, United Kingdom
| | - Zsuzsanna Lakos
- Biochemistry Method Development & Validation, Eurofins Lancaster Laboratories, Inc., 2425 New Holland Pike Lancaster, Pennsylvania 17601
| | - Yanming An
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - John F Cipollo
- Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993
| | - Maja Pucic-Bakovic
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Jerko Štambuk
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia
| | - Gordan Lauc
- Glycoscience Research Laboratory, Genos, Borongajska cesta 83h, 10 000 Zagreb, Croatia; Faculty of Pharmacy and Biochemistry, University of Zagreb, A. Kovačića 1, 10 000 Zagreb, Croatia
| | - Xu Li
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Peng George Wang
- Department of Chemistry, Georgia State University, 100 Piedmont Avenue, Atlanta, Georgia 30303
| | - Andreas Bock
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - René Hennig
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany
| | - Erdmann Rapp
- glyXera GmbH, Brenneckestrasse 20 * ZENIT / 39120 Magdeburg, Germany; AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Marybeth Creskey
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Terry D Cyr
- Health Products and Foods Branch, Health Canada, AL 2201E, 251 Sir Frederick Banting Driveway, Ottawa, Ontario, K1A 0K9 Canada
| | - Miyako Nakano
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | - Taiki Sugiyama
- Graduate School of Advanced Sciences of Matter, Hiroshima University, 1-3-1 Kagamiyama Higashi-Hiroshima 739-8530 Japan
| | | | - Paweł Link-Lenczowski
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Jolanta Jaworek
- Department of Medical Physiology, Jagiellonian University Medical College, ul. Michalowskiego 12, 31-126 Krakow, Poland
| | - Shuang Yang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Hui Zhang
- Department of Pathology, Johns Hopkins University, 400 N. Broadway Street Baltimore, Maryland 21287
| | - Tim Kelly
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Song Klapoetke
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Rui Cao
- Mass Spec Core Facility, KBI Biopharma, 1101 Hamlin Road Durham, North Carolina 27704
| | - Jin Young Kim
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Hyun Kyoung Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Ju Yeon Lee
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Jong Shin Yoo
- Division of Mass Spectrometry, Korea Basic Science Institute, 162 YeonGuDanji-Ro, Ochang-eup, Cheongwon-gu, Cheongju Chungbuk, 363-883 Korea (South)
| | - Sa-Rang Kim
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Soo-Kyung Suh
- Advanced Therapy Products Research Division, Korea National Institute of Food and Drug Safety, 187 Osongsaengmyeong 2-ro Osong-eup, Heungdeok-gu, Cheongju-si, Chungcheongbuk-do, 363-700, Korea (South)
| | - Noortje de Haan
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - David Falck
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | | | - Manfred Wuhrer
- Center for Proteomics and Metabolomics, Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The Netherlands
| | - Robert J Emery
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Radoslaw P Kozak
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Li Phing Liew
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Louise Royle
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Paulina A Urbanowicz
- Ludger Limited, Culham Science Centre, Abingdon, Oxfordshire, OX14 3EB, United Kingdom
| | - Nicolle H Packer
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Xiaomin Song
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Arun Everest-Dass
- Biomolecular Discovery and Design Research Centre and ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP), Macquarie University, North Ryde, Australia
| | - Erika Lattová
- Proteomics, Central European Institute for Technology, Masaryk University, Kamenice 5, A26, 625 00 BRNO, Czech Republic
| | - Samanta Cajic
- Max Planck Institute for Dynamics of Complex Technical Systems, Sandtorstrasse 1, 39106 Magdeburg, Germany
| | - Kathirvel Alagesan
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Daniel Kolarich
- Department of Biomolecular Sciences, Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, Germany
| | - Toyin Kasali
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Viv Lindo
- AstraZeneca, Granta Park, Cambridgeshire, CB21 6GH United Kingdom
| | - Yuetian Chen
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Kudrat Goswami
- Merck, 2015 Galloping Hill Rd, Kenilworth, New Jersey 07033
| | - Brian Gau
- Analytical R&D, MilliporeSigma, 2909 Laclede Ave. St. Louis, Missouri 63103
| | - Ravi Amunugama
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | - Richard Jones
- MS Bioworks, LLC, 3950 Varsity Drive Ann Arbor, Michigan 48108
| | | | - Koichi Kato
- Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, 5-1 Higashiyama, Myodaiji, Okazaki 444-8787 Japan; Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Hirokazu Yagi
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan
| | - Sachiko Kondo
- Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabe-dori, Mizuhoku, Nagoya 467-8603 Japan; Medical & Biological Laboratories Co., Ltd, 2-22-8 Chikusa, Chikusa-ku, Nagoya 464-0858 Japan
| | - C T Yuen
- National Institute for Biological Standards and Control, Blanche Lane, South Mimms, Potters Bar, Hertfordshire EN6 3QG United Kingdom
| | - Akira Harazono
- Division of Biological Chemistry & Biologicals, National Institute of Health Sciences, 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501 Japan
| | - Xiaofeng Shi
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Paula E Magnelli
- New England Biolabs, Inc., 240 County Road, Ipswich, Massachusetts 01938
| | - Brian T Kasper
- New York University, 100 Washington Square East New York City, New York 10003
| | - Lara Mahal
- New York University, 100 Washington Square East New York City, New York 10003
| | - David J Harvey
- Target Discovery Institute, Nuffield Department of Medicine, University of Oxford, Roosevelt Drive, Oxford, OX3 7FZ, United Kingdom
| | - Roisin O'Flaherty
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Pauline M Rudd
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Radka Saldova
- GlycoScience Group, The National Institute for Bioprocessing Research and Training, Fosters Avenue, Mount Merrion, Blackrock, Co. Dublin, Ireland
| | - Elizabeth S Hecht
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - David C Muddiman
- Department of Chemistry, North Carolina State University, 2620 Yarborough Drive Raleigh, North Carolina 27695
| | - Jichao Kang
- Pantheon, 201 College Road East Princeton, New Jersey 08540
| | | | | | - Andrew Saati
- Pfizer Inc., 1 Burtt Road Andover, Massachusetts 01810
| | - Christine Merle
- Proteodynamics, ZI La Varenne 20-22 rue Henri et Gilberte Goudier 63200 RIOM, France
| | - Steven Mast
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Sam Tep
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Jennie Truong
- ProZyme, Inc., 3832 Bay Center Place Hayward, California 94545
| | - Takashi Nishikaze
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Sadanori Sekiya
- Koichi Tanaka Mass Spectrometry Research Laboratory, Shimadzu Corporation, 1 Nishinokyo Kuwabara-cho Nakagyo-ku, Kyoto, 604 8511 Japan
| | - Aaron Shafer
- Children's GMP LLC, St. Jude Children's Research Hospital, 262 Danny Thomas Place Memphis, Tennessee 38105
| | - Sohei Funaoka
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Masaaki Toyoda
- Sumitomo Bakelite Co., Ltd., 1-5 Muromati 1-Chome, Nishiku, Kobe, 651-2241 Japan
| | - Peter de Vreugd
- Synthon Biopharmaceuticals, Microweg 22 P.O. Box 7071, 6503 GN Nijmegen, The Netherlands
| | - Cassie Caron
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Pralima Pradhan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Niclas Chiang Tan
- Takeda Pharmaceuticals International Co., 40 Landsdowne Street Cambridge, Massachusetts 02139
| | - Yehia Mechref
- Department of Chemistry and Biochemistry, Texas Tech University, 2500 Broadway, Lubbock, Texas 79409
| | - Sachin Patil
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Jeffrey S Rohrer
- Thermo Fisher Scientific, 1214 Oakmead Parkway Sunnyvale, California 94085
| | - Ranjan Chakrabarti
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Disha Dadke
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Mohammedazam Lahori
- United States Pharmacopeia India Pvt. Ltd. IKP Knowledge Park, Genome Valley, Shamirpet, Turkapally Village, Medchal District, Hyderabad 500 101 Telangana, India
| | - Chunxia Zou
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Christopher Cairo
- Alberta Glycomics Centre, University of Alberta, Edmonton, Alberta T6G 2G2 Canada; Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Béla Reiz
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Randy M Whittal
- Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2 Canada
| | - Carlito B Lebrilla
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Lauren Wu
- Department of Chemistry, University of California, One Shields Ave, Davis, California 95616
| | - Andras Guttman
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary
| | - Marton Szigeti
- Horváth Csaba Memorial Laboratory for Bioseparation Sciences, Research Center for Molecular Medicine, Doctoral School of Molecular Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Egyetem ter 1, Hungary; Translational Glycomics Research Group, Research Institute of Biomolecular and Chemical Engineering, University of Pannonia, Veszprem, Egyetem ut 10, Hungary
| | - Benjamin G Kremkow
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Kelvin H Lee
- Delaware Biotechnology Institute, University of Delaware, 15 Innovation Way Newark, Delaware 19711
| | - Carina Sihlbom
- Proteomics Core Facility, University of Gothenburg, Medicinaregatan 1G SE 41390 Gothenburg, Sweden
| | - Barbara Adamczyk
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Chunsheng Jin
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Niclas G Karlsson
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Jessica Örnros
- Department of Medical Biochemistry and Cell Biology, University of Gothenburg, Institute of Biomedicine, Sahlgrenska Academy, Medicinaregatan 9A, Box 440, 405 30, Gothenburg, Sweden
| | - Göran Larson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Jonas Nilsson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Bruna Straket 16, 41345 Gothenburg, Sweden
| | - Bernd Meyer
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Alena Wiegandt
- Department of Chemistry, University of Hamburg, Martin Luther King Pl. 6 20146 Hamburg, Germany
| | - Emy Komatsu
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Helene Perreault
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2
| | - Edward D Bodnar
- Department of Chemistry, University of Manitoba, 144 Dysart Road, Winnipeg, Manitoba, Canada R3T 2N2; Agilent Technologies, Inc., 5301 Stevens Creek Blvd Santa Clara, California 95051
| | - Nassur Said
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Yannis-Nicolas Francois
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Emmanuelle Leize-Wagner
- Laboratory of Mass Spectrometry of Interactions and Systems, University of Strasbourg, UMR Unistra-CNRS 7140, France
| | - Sandra Maier
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Anne Zeck
- Natural and Medical Sciences Institute, University of Tübingen, Markwiesenstraβe 55, 72770 Reutlingen, Germany
| | - Albert J R Heck
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Yang Yang
- Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, Utrecht University, Padualaan 8, 3584 CH Utrecht, The Netherlands
| | - Rob Haselberg
- Division of Bioanalytical Chemistry, Amsterdam Institute for Molecules, Medicines and Systems, Vrije Universiteit Amsterdam, de Boelelaan 1085, 1081 HV Amsterdam, The Netherlands
| | - Ying Qing Yu
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | - William Alley
- Department of Chemistry, Waters Corporation, 34 Maple Street Milford, Massachusetts 01757
| | | | - Hua Yuan
- Zoetis, 333 Portage St. Kalamazoo, Michigan 49007
| | - Stephen E Stein
- Mass Spectrometry Data Center, Biomolecular Measurement Division, Material Measurement Laboratory, National Institute of Standards and Technology, 100 Bureau Drive Gaithersburg, Maryland 20899
| |
Collapse
|
10
|
Howlader MA, Li C, Zou C, Chakraberty R, Ebesoh N, Cairo CW. Neuraminidase-3 Is a Negative Regulator of LFA-1 Adhesion. Front Chem 2019; 7:791. [PMID: 31824923 PMCID: PMC6882948 DOI: 10.3389/fchem.2019.00791] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2019] [Accepted: 11/04/2019] [Indexed: 01/13/2023] Open
Abstract
Within the plasma membrane environment, glycoconjugate-receptor interactions play an important role in the regulation of cell-cell interactions. We have investigated the mechanism and activity of the human neuraminidase (NEU) isoenzyme, NEU3, on T cell adhesion receptors. The enzyme is known to prefer glycolipid substrates, and we confirmed that exogenous enzyme altered the glycolipid composition of cells. NEU3 was able to modify the sialic acid content of purified LFA-1 in vitro. Enzymatic activity of NEU3 resulted in re-organization of LFA-1 into large clusters on the membrane. This change was facilitated by an increase in the lateral mobility of LFA-1 upon NEU3 treatment. Changes to the lateral mobility of LFA-1 were specific for NEU3 activity, and we observed no significant change in diffusion when cells were treated with a bacterial NEU (NanI). Furthermore, we found that NEU3 treatment of cells increased surface expression levels of LFA-1. We observed that NEU3-treated cells had suppressed LFA-1 adhesion to an ICAM-1 coated surface using an in vitro static adhesion assay. These results establish that NEU3 can modulate glycoconjugate composition and contribute to the regulation of integrin activity. We propose that NEU3 should be investigated to determine its role on LFA-1 within the inflammatory cascade.
Collapse
Affiliation(s)
- Md Amran Howlader
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Caishun Li
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Chunxia Zou
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | | | - Njuacha Ebesoh
- Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | | |
Collapse
|
11
|
Han C, Xian Z, Zou Y, Liao Z, Yang R, Zou C, Wang X, Sun Y. Flow-mediated dilation can be used to predict incident hypertension in patients with hyperuricemia. Arch Med Sci 2019; 15:343-349. [PMID: 30899286 PMCID: PMC6425196 DOI: 10.5114/aoms.2018.73856] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/10/2017] [Accepted: 12/30/2017] [Indexed: 11/25/2022] Open
Abstract
INTRODUCTION The aim of the study was to evaluate whether flow-mediated dilation (FMD) can be used to predict incident hypertension in patients with hyperuricemia. MATERIAL AND METHODS Normotensive participants with and without hyperuricemia at baseline were prospectively enrolled. Flow-mediated dilation was assessed at baseline, and after 1 year's follow-up the incidence of hypertension was compared between those with and without hyperuricemia. The predictive value of baseline FMD for incident hypertension among hyperuricemia patients was evaluated. RESULTS A total of 222 participants were included. Mean systolic and diastolic blood pressure (BP) was 129.5 ±8.4 mm Hg and 78.3 ±7.9 mm Hg. Mean serum uric acid (UA) level was 4.4 ±2.8 mg/dl. Mean FMD was 5.1 ±2.7%. Compared to normal UA group, hyperuricemia group had higher proportion of male (58.4% vs. 61.2%), higher systolic BP (125.4 ±7.9 mm Hg vs. 132.1 ±7.3 mm Hg), serum high sensitivity C-reactive protein (3.9 ±2.2 mg/dl vs. 4.5 ±3.0 mg/dl) and UA (3.5 ±1.4 mg/dl vs. 5.7 ±0.7 mg/dl) levels, but lower mean FMD (5.6 ±2.4% vs. 4.8 ±2.0%) (p < 0.05 for all comparisons). No participant in normal UA group developed hypertension, while in hyperuricemia group, 6 participants developed hypertension. In hyperuricemia participants, after adjusted for covariates, per 1-standard deviation decrease in baseline FMD remained significantly associated with 15% increased risk of incident hypertension. CONCLUSIONS Patients with hyperuricemia have an increased risk of developing hypertension, and low baseline FMD in hyperuricemia patients is associated with significantly increased risk of incident hypertension.
Collapse
Affiliation(s)
- Chunli Han
- Department of Cardiology, the Fifth Subsidiary Sun Yat-sen University Hospital, Zhuhai, China
| | - Zhanchao Xian
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Yang Zou
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Zhiyong Liao
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Rongfeng Yang
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Chunxia Zou
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Xiaoqing Wang
- Department of Cardiology, Shenzhen Sun Yat-sen Cardiovascular Hospital, Shenzhen, China
| | - Yan Sun
- Department of Endocrinology, Xili People’s Hospital of Nanshan District, Shenzhen, China
| |
Collapse
|
12
|
Katz R, Bukanova E, Blessing M, Zou C, Ostroff R. Four cases of procedural consolidation with electroconvulsive therapy. Brain Stimul 2019. [DOI: 10.1016/j.brs.2018.12.415] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
|
13
|
Wei Y, Xiong ZJ, Li J, Zou C, Cairo CW, Klassen JS, Privé GG. Crystal structures of human lysosomal EPDR1 reveal homology with the superfamily of bacterial lipoprotein transporters. Commun Biol 2019; 2:52. [PMID: 30729188 PMCID: PMC6363788 DOI: 10.1038/s42003-018-0262-9] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2018] [Accepted: 12/11/2018] [Indexed: 01/01/2023] Open
Abstract
EPDR1, a member of the ependymin-related protein family, is a relatively uncharacterized protein found in the lysosomes and secretomes of most vertebrates. Despite having roles in human disease and health, the molecular functions of EPDR1 remain unknown. Here, we present crystal structures of human EPDR1 and reveal that the protein adopts a fold previously seen only in bacterial proteins related to the LolA lipoprotein transporter. EPDR1 forms a homodimer with an overall shape resembling a half-shell with two non-overlapping hydrophobic grooves on the flat side of the hemisphere. EPDR1 can interact with membranes that contain negatively charged lipids, including BMP and GM1, and we suggest that EPDR1 may function as a lysosomal activator protein or a lipid transporter. A phylogenetic analysis reveals that the fold is more widely distributed than previously suspected, with representatives identified in all branches of cellular life.
Collapse
Affiliation(s)
- Yong Wei
- Princess Margaret Cancer Centre, Toronto, M5G 1L7 ON Canada
| | - Zi Jian Xiong
- Department of Biochemistry, University of Toronto, Toronto, M5S 1A8 ON Canada
| | - Jun Li
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2 AB Canada
| | - Chunxia Zou
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2 AB Canada
| | - Christopher W. Cairo
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2 AB Canada
| | - John S. Klassen
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2 AB Canada
| | - Gilbert G. Privé
- Princess Margaret Cancer Centre, Toronto, M5G 1L7 ON Canada
- Department of Biochemistry, University of Toronto, Toronto, M5S 1A8 ON Canada
- Department of Medical Biophysics, University of Toronto, Toronto, M5G 1L7 ON Canada
| |
Collapse
|
14
|
Abstract
Inhibitors of human neuraminidase enzymes (NEU) are recognized as important tools for the study of the biological functions of NEU and will be potent tools for elucidating the role of these enzymes in regulating the repertoire of cellular glycans. Here we report the discovery of selective inhibitors of the human neuraminidase 1 (NEU1) and neuraminidase 2 (NEU2) enzymes with exceptional potency. A library of modified 2-deoxy-2,3-didehydro- N-acetylneuraminic acid (DANA) analogues, with variability in the C5- or C9-position, were synthesized and evaluated against four human neuraminidase isoenyzmes (NEU1-4). Hydrophobic groups with an amide linker at the C5 and C9 positions were well accommodated by NEU1, and a hexanamido group was found to give the best potency at both positions. While the C5-hexanamido-C9-hexanamido-DANA analogue did not show synergistic improvements for combined modification, an extended alkylamide at an individual position combined with a smaller group at the second gave increased potency. The best NEU1 inhibitor identified was a C5-hexanamido-C9-acetamido-DANA that had a Ki of 53 ± 5 nM and 340-fold selectivity over other isoenzymes. Additionally, we demonstrated that C5-modifications combined with a C4-guandino group provided the most potent NEU2 inhibitor reported, with a Ki of 1.3 ± 0.2 μM and 7-fold selectivity over other NEU isoenzymes.
Collapse
Affiliation(s)
- Tianlin Guo
- Alberta Glycomics Centre, Department of Chemistry , University of Alberta , Edmonton , Alberta T6G 2G2 , Canada
| | - Rachel Héon-Roberts
- Division of Medical Genetics , Sainte-Justine University Hospital Research Center, University of Montreal , Montréal , H3T 1C5 , Canada
| | - Chunxia Zou
- Alberta Glycomics Centre, Department of Chemistry , University of Alberta , Edmonton , Alberta T6G 2G2 , Canada
| | - Ruixiang Zheng
- Alberta Glycomics Centre, Department of Chemistry , University of Alberta , Edmonton , Alberta T6G 2G2 , Canada
| | - Alexey V Pshezhetsky
- Division of Medical Genetics , Sainte-Justine University Hospital Research Center, University of Montreal , Montréal , H3T 1C5 , Canada
| | - Christopher W Cairo
- Alberta Glycomics Centre, Department of Chemistry , University of Alberta , Edmonton , Alberta T6G 2G2 , Canada
| |
Collapse
|
15
|
Demina EP, Pierre WC, Nguyen ALA, Londono I, Reiz B, Zou C, Chakraberty R, Cairo CW, Pshezhetsky AV, Lodygensky GA. Persistent reduction in sialylation of cerebral glycoproteins following postnatal inflammatory exposure. J Neuroinflammation 2018; 15:336. [PMID: 30518374 PMCID: PMC6282350 DOI: 10.1186/s12974-018-1367-2] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/21/2018] [Accepted: 11/14/2018] [Indexed: 12/17/2022] Open
Abstract
BACKGROUND The extension of sepsis encompassing the preterm newborn's brain is often overlooked due to technical challenges in this highly vulnerable population, yet it leads to substantial long-term neurodevelopmental disabilities. In this study, we demonstrate how neonatal neuroinflammation following postnatal E. coli lipopolysaccharide (LPS) exposure in rat pups results in persistent reduction in sialylation of cerebral glycoproteins. METHODS Male Sprague-Dawley rat pups at postnatal day 3 (P3) were injected in the corpus callosum with saline or LPS. Twenty-four hours (P4) or 21 days (P24) following injection, brains were extracted and analyzed for neuraminidase activity and expression as well as for sialylation of cerebral glycoproteins and glycolipids. RESULTS At both P4 and P24, we detected a significant increase of the acidic neuraminidase activity in LPS-exposed rats. It correlated with significantly increased neuraminidase 1 (Neu1) mRNA in LPS-treated brains at P4 and with neuraminidases 1 and 4 at P24 suggesting that these enzymes were responsible for the rise of neuraminidase activity. At both P4 and P24, sialylation of N-glycans on brain glycoproteins decreased according to both mass-spectrometry analysis and lectin blotting, but the ganglioside composition remained intact. Finally, at P24, analysis of brain tissues by immunohistochemistry showed that neurons in the upper layers (II-III) of somatosensory cortex had a reduced surface content of polysialic acid. CONCLUSIONS Together, our data demonstrate that neonatal LPS exposure results in specific and sustained induction of Neu1 and Neu4, causing long-lasting negative changes in sialylation of glycoproteins on brain cells. Considering the important roles played by sialoglycoproteins in CNS function, we speculate that observed re-programming of the brain sialome constitutes an important part of pathophysiological consequences in perinatal infectious exposure.
Collapse
Affiliation(s)
- Ekaterina P Demina
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
| | - Wyston C Pierre
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
| | - Annie L A Nguyen
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
| | - Irene Londono
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada
| | - Bela Reiz
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, AB, Canada
| | - Chunxia Zou
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, AB, Canada
| | - Radhika Chakraberty
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, AB, Canada
| | - Christopher W Cairo
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, AB, Canada
| | - Alexey V Pshezhetsky
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada. .,Department of Anatomy and Cell Biology, McGill University, Montreal, H3A0C7, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, 3175 Côte-Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
| | - Gregory A Lodygensky
- Department of Paediatrics, Sainte-Justine Hospital Research Center, Université de Montréal, Montreal, H3T 1C5, QC, Canada. .,Department of Pharmacology and Physiology, Université de Montréal, Montreal, H3T 1J4, QC, Canada. .,Montreal Heart Institute, Montreal, H1T 1C8, QC, Canada. .,Centre de recherche, CHU Sainte-Justine, 3175 Côte-Sainte-Catherine, Montreal, QC, H3T 1C5, Canada.
| |
Collapse
|
16
|
Chan JTH, Liu Y, Khan S, St-Germain JR, Zou C, Leung LYT, Yang J, Shi M, Grunebaum E, Campisi P, Propst EJ, Holler T, Bar-Or A, Wither JE, Cairo CW, Moran MF, Palazzo AF, Cooper MD, Ehrhardt GRA. A tyrosine sulfation-dependent HLA-I modification identifies memory B cells and plasma cells. Sci Adv 2018; 4:eaar7653. [PMID: 30417091 PMCID: PMC6221509 DOI: 10.1126/sciadv.aar7653] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/14/2017] [Accepted: 10/12/2018] [Indexed: 06/09/2023]
Abstract
Memory B cells and plasma cells are antigen-experienced cells tasked with the maintenance of humoral protection. Despite these prominent functions, definitive cell surface markers have not been identified for these cells. We report here the isolation and characterization of the monoclonal variable lymphocyte receptor B (VLRB) N8 antibody from the evolutionarily distant sea lamprey that specifically recognizes memory B cells and plasma cells in humans. Unexpectedly, we determined that VLRB N8 recognizes the human leukocyte antigen-I (HLA-I) antigen in a tyrosine sulfation-dependent manner. Furthermore, we observed increased binding of VLRB N8 to memory B cells in individuals with autoimmune disorders multiple sclerosis and systemic lupus erythematosus. Our study indicates that lamprey VLR antibodies uniquely recognize a memory B cell- and plasma cell-specific posttranslational modification of HLA-I, the expression of which is up-regulated during B cell activation.
Collapse
Affiliation(s)
- Justin T. H. Chan
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Yanling Liu
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Srijit Khan
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | | | - Chunxia Zou
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | | | - Judi Yang
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Mengyao Shi
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Eyal Grunebaum
- Division of Immunology and Allergy, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
| | - Paolo Campisi
- Department of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
| | - Evan J. Propst
- Department of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
| | - Theresa Holler
- Department of Otolaryngology-Head and Neck Surgery, Hospital for Sick Children and University of Toronto, Toronto, ON, Canada
| | - Amit Bar-Or
- Department of Neurology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA
| | - Joan E. Wither
- Department of Immunology, University of Toronto, Toronto, ON, Canada
| | - Christopher W. Cairo
- Alberta Glycomics Centre and Department of Chemistry, University of Alberta, Edmonton, AB, Canada
| | - Michael F. Moran
- Department of Molecular Genetics, Hospital for Sick Children, Toronto, ON, Canada
| | | | - Max D. Cooper
- Department of Pathology and Laboratory Medicine and Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA
| | | |
Collapse
|
17
|
Menth R, Zou C, Romero L, Turner E, Huang K, Gibson A, McWilliams-Koeppen P, Chase B. Development of highly sensitive and specific in vitro renal solute carrier (SLC) uptake cell models using normal human adult renal proximal tubule epithelial cells for drug transporter interaction studies. Toxicol Lett 2018. [DOI: 10.1016/j.toxlet.2018.06.650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
18
|
Vinals DF, Kitov PI, Tu Z, Zou C, Cairo CW, Lin HCH, Derda R. Selection of galectin-3 ligands derived from genetically encoded glycopeptide libraries. Pept Sci (Hoboken) 2018. [DOI: 10.1002/pep2.24097] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
| | - Pavel I. Kitov
- Department of Chemistry; University of Alberta; Edmonton Alberta Canada
| | - Zhijay Tu
- Institute of Biological Chemistry, Academia Sinica; Taipei Taiwan
| | - Chunxia Zou
- Department of Chemistry; University of Alberta; Edmonton Alberta Canada
| | | | | | - Ratmir Derda
- Department of Chemistry; University of Alberta; Edmonton Alberta Canada
| |
Collapse
|
19
|
Bi Q, Xiao Z, Lv F, Liu Y, Zou C, Shen Y. Utility of Clinical Parameters and Multiparametric MRI as Predictive Factors for Differentiating Uterine Sarcoma From Atypical Leiomyoma. Acad Radiol 2018; 25:993-1002. [PMID: 29422425 DOI: 10.1016/j.acra.2018.01.002] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2017] [Revised: 01/09/2018] [Accepted: 01/09/2018] [Indexed: 02/08/2023]
Abstract
OBJECTIVES The objective of this study was to find clinical parameters and qualitative and quantitative magnetic resonance imaging (MRI) features for differentiating uterine sarcoma from atypical leiomyoma (ALM) preoperatively and to calculate predictive values for uterine sarcoma. MATERIALS AND METHODS Data from 60 patients with uterine sarcoma and 88 patients with ALM confirmed by surgery and pathology were collected. Clinical parameters, qualitative MRI features, diffusion-weighted imaging with apparent diffusion coefficient values, and quantitative parameters of dynamic contrast-enhanced MRI of these two tumor types were compared. Predictive values for uterine sarcoma were calculated using multivariable logistic regression. RESULTS Patient clinical manifestations, tumor locations, margins, T2-weighted imaging signals, mean apparent diffusion coefficient values, minimum apparent diffusion coefficient values, and time-signal intensity curves of solid tumor components were obvious significant parameters for distinguishing between uterine sarcoma and ALM (all P <.001). Abnormal vaginal bleeding, tumors located mainly in the uterine cavity, ill-defined tumor margins, and mean apparent diffusion coefficient values of <1.272 × 10-3 mm2/s were significant preoperative predictors of uterine sarcoma. When the overall scores of these four predictors were greater than or equal to 7 points, the sensitivity, the specificity, the accuracy, and the positive and negative predictive values were 88.9%, 99.9%, 95.7%, 97.0%, and 95.1%, respectively. CONCLUSIONS The use of clinical parameters and multiparametric MRI as predictive factors was beneficial for diagnosing uterine sarcoma preoperatively. These findings could be helpful for guiding treatment decisions.
Collapse
|
20
|
Chen X, Xu Z, Zhang F, Zou C, Zhu Y, Zhong H, Zhu S. PO-039 Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.84] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
|
21
|
Xu Z, Zhang F, Zhu Y, Yao C, Zhong H, Zhu S, Zou C, Chen X. PO-036 Traditional chinese medicine Ze-Qi-TANG formula induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in lung cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
22
|
Xu Z, Zhang F, Zhu Y, Yao C, Zhong H, Zhu S, Zou C, Chen X. PO-054 Traditional chinese medicine Ze-Qi-tang formula induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in lung cancer. ESMO Open 2018. [DOI: 10.1136/esmoopen-2018-eacr25.98] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
23
|
Demina EP, Smutova V, Fougerat A, Guo T, Zou C, Miyagi T, Laffargue M, Cairo CW, Pshezhetsky AV. Inhibitors of Lysosomal Neuraminidases 1 and 3 as Potential Candidates for Treating Atherosclerosis. ATHEROSCLEROSIS SUPP 2018. [DOI: 10.1016/j.atherosclerosissup.2018.04.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
24
|
Yang YC, Zou C. [Surgical treatment of cronic rhinosinusitis with nasal polyps]. Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2018; 32:328-331. [PMID: 29798287 DOI: 10.13201/j.issn.1001-1781.2018.05.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Key Words] [Subscribe] [Scholar Register] [Received: 12/04/2017] [Indexed: 11/12/2022]
|
25
|
Hunter CD, Khanna N, Richards MR, Rezaei Darestani R, Zou C, Klassen JS, Cairo CW. Human Neuraminidase Isoenzymes Show Variable Activities for 9- O-Acetyl-sialoside Substrates. ACS Chem Biol 2018; 13:922-932. [PMID: 29341588 DOI: 10.1021/acschembio.7b00952] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Recognition of terminal sialic acids is central to many cellular processes, and structural modification of sialic acid can disrupt these interactions. A prominent, naturally occurring, modification of sialic acid is 9- O-acetylation (9- O-Ac). Study of this modification through generation and analysis of 9- O-Ac sialosides is challenging because of the lability of the acetate group. Fundamental questions regarding the role of 9- O-Ac sialic acids remain unanswered, including what effect it may have on recognition and hydrolysis by the human neuraminidase enzymes (hNEU). To investigate the substrate activity of 9- O-acetylated sialic acids (Neu5,9Ac2), we synthesized an acetylated fluorogenic hNEU substrate 2'-(4-methylumbelliferyl)-9- O-acetyl-α-d- N-acetylneuraminic acid. Additionally, we generated a panel of octyl sialyllactosides containing modified sialic acids including variation in linkage, 9- O-acetylation, and C-5 group (Neu5Gc). Relative rates of substrate cleavage by hNEU were determined using fluorescence spectroscopy and electrospray ionization mass spectrometry. We report that 9- O-acetylation had a significant, and differential, impact on sialic acid hydrolysis by hNEU with general substrate tolerance following the trend of Neu5Ac > Neu5Gc ≫ Neu5,9Ac2 for NEU2, NEU3, and NEU4. Both NEU2 and NEU3 had remarkably reduced activity for Neu5,9Ac2 containing substrates. Other isoenzymes appeared to be more tolerant, with NEU4 even showing increased activity on Neu5,9Ac2 substrates with an aryl aglycone. The impact of these minor structural changes to sialic acid on hNEU activity was unexpected, and these results provide evidence of the substantial influence of 9- O-Ac modifications on hNEU enzyme substrate specificity. Furthermore, these findings may implicate hNEU in processes governed by 9- O-acetyltransferases and -esterases.
Collapse
Affiliation(s)
- Carmanah D. Hunter
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - Neha Khanna
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - Michele R. Richards
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - Reza Rezaei Darestani
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - Chunxia Zou
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - John S. Klassen
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| | - Christopher W. Cairo
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta T6G 2G2, Canada
| |
Collapse
|
26
|
Guo T, Dätwyler P, Demina E, Richards MR, Ge P, Zou C, Zheng R, Fougerat A, Pshezhetsky AV, Ernst B, Cairo CW. Selective Inhibitors of Human Neuraminidase 3. J Med Chem 2018; 61:1990-2008. [PMID: 29425031 DOI: 10.1021/acs.jmedchem.7b01574] [Citation(s) in RCA: 38] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Human neuraminidases (NEU) are associated with human diseases including cancer, atherosclerosis, and diabetes. To obtain small molecule inhibitors as research tools for the study of their biological functions, we designed a library of 2-deoxy-2,3-didehydro- N-acetylneuraminic acid (DANA) analogues with modifications at C4 and C9 positions. This library allowed us to discover selective inhibitors targeting the human NEU3 isoenzyme. Our most selective inhibitor for NEU3 has a Ki of 320 ± 40 nM and a 15-fold selectivity over other human neuraminidase isoenzymes. This inhibitor blocks glycolipid processing by NEU3 in vitro. To improve their pharmacokinetic properties, various esters of the best inhibitors were synthesized and evaluated. Finally, we confirmed that our best compounds exhibited selective inhibition of NEU orthologues from murine brain.
Collapse
Affiliation(s)
- Tianlin Guo
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Philipp Dätwyler
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Ekaterina Demina
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Michele R Richards
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Peng Ge
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Chunxia Zou
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Ruixiang Zheng
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| | - Anne Fougerat
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Alexey V Pshezhetsky
- Division of Medical Genetics, Sainte-Justine University Hospital Research Center , University of Montreal , Montréal , Quebec H3T 1C5 , Canada
| | - Beat Ernst
- Department of Pharmaceutical Sciences, Pharmacenter , University of Basel , Klingelbergstrasse 50 , CH-4056 Basel , Switzerland
| | - Christopher W Cairo
- Alberta Glycomics Centre and Department of Chemistry , University of Alberta , Edmonton Alberta T6G 2G2 , Canada
| |
Collapse
|
27
|
Zhang Q, Zhou Y, Majaw JK, Xu J, Wei Z, Mai Q, Zou C, Zhang Y, Fan Z, Huang F, Sun J, Liu Q, Jiang Q. Acute appendicitis in leukaemia patients undergoing haematopoietic stem cell transplantation during the neutropaenic phase: a case series from a single BMT centre in China. Bone Marrow Transplant 2018; 53:219-222. [PMID: 29410536 DOI: 10.1038/bmt.2017.209] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
28
|
Yang EH, Rode J, Howlader MA, Eckermann M, Santos JT, Hernandez Armada D, Zheng R, Zou C, Cairo CW. Galectin-3 alters the lateral mobility and clustering of β1-integrin receptors. PLoS One 2017; 12:e0184378. [PMID: 29016609 PMCID: PMC5634555 DOI: 10.1371/journal.pone.0184378] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2017] [Accepted: 08/22/2017] [Indexed: 01/25/2023] Open
Abstract
Glycoprotein receptors are influenced by myriad intermolecular interactions at the cell surface. Specific glycan structures may interact with endogenous lectins that enforce or disrupt receptor-receptor interactions. Glycoproteins bound by multivalent lectins may form extended oligomers or lattices, altering the lateral mobility of the receptor and influencing its function through endocytosis or changes in activation. In this study, we have examined the interaction of Galectin-3 (Gal-3), a human lectin, with adhesion receptors. We measured the effect of recombinant Gal-3 added exogenously on the lateral mobility of the α5β1 integrin on HeLa cells. Using single-particle tracking (SPT) we detected increased lateral mobility of the integrin in the presence of Gal-3, while its truncated C-terminal domain (Gal-3C) showed only minor reductions in lateral mobility. Treatment of cells with Gal-3 increased β1-integrin mediated migration with no apparent changes in viability. In contrast, Gal-3C decreased both cell migration and viability. Fluorescence microscopy allowed us to confirm that exogenous Gal-3 resulted in reorganization of the integrin into larger clusters. We used a proteomics analysis to confirm that cells expressed endogenous Gal-3, and found that addition of competitive oligosaccharide ligands for the lectin altered the lateral mobility of the integrin. Together, our results are consistent with a Gal-3-integrin lattice model of binding and confirm that the lateral mobility of integrins is natively regulated, in part, by galectins.
Collapse
Affiliation(s)
- Esther H. Yang
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Julia Rode
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Md. Amran Howlader
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Marina Eckermann
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Jobette T. Santos
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Daniel Hernandez Armada
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Ruixiang Zheng
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Chunxia Zou
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
| | - Christopher W. Cairo
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton Alberta, Canada
- * E-mail:
| |
Collapse
|
29
|
Wang FY, Zou C, Dong HK, Yang YC, Gao MW, Zhao R, Jin JL, Yang XJ. [Analysis of influencing factors of heart rate deceleration capacity in patients with dilated cardiomyopathy]. Zhonghua Xin Xue Guan Bing Za Zhi 2017; 45:753-757. [PMID: 29036972 DOI: 10.3760/cma.j.issn.0253-3758.2017.09.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To investigate the determinants affecting the heart rate deceleration capacity (DC) in patients with dilated cardiomyopathy (DCM). Methods: One hundred patients with DCM (DCM group) and 202 healthy subjects (control group) were respectively enrolled. Echocardiography and 24 hours electrocardiogram were performed in all subjects. DC value was compared between the two groups. Multiple regression analysis was made to evaluate the related determinants of DC ((age, sex, echocardiographic parameters including the left atrial diameter (LAD) and left ventricular ejection fraction (LVEF)). Results: (1) DC value was significantly lower in DCM group than in control group( (4.40±2.03) ms vs. (7.30±1.81) ms, P<0.01), prevalence of DC value≤4.5 ms was significantly higher in DCM group than in control group (62% vs. 6%, P<0.01). (2) DC value in the DCM group decreased in proportion to increasing LAD dimension, DC value was (5.60±2.04) ms, (4.50±2.07) ms and (3.60±1.62) ms (P<0.05) in DCM patients with LAD≤40 mm, 40 mm<LAD≤50 mm and LAD>50 mm, respectively. (3) DC value in the DCM group was negatively related to the LAD (r=-0.366, P<0.01), positively related to the LVEF (r= 0.241, P<0.01), but not related with age and sex. Multiple factors regression analysis showed that increased LAD was related to the reduced DC values independtly. Conclusion: DC value of the patients in the DCM group is decreased, which indicate the decrease of the vagus nerve tension, and increased LAD is related to the reduced DC value independtly in DCM patients.
Collapse
Affiliation(s)
- F Y Wang
- Department of Cardiology, First Affiliated Hospital of Soochow University, Suzhou 215006, China
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Li L, Zou C, Zhou Z, Yu X. Effects of herbal medicine Sijunzi decoction on rabbits after relieving intestinal obstruction. ACTA ACUST UNITED AC 2017; 50:e6331. [PMID: 28953987 PMCID: PMC5609600 DOI: 10.1590/1414-431x20176331] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/25/2017] [Accepted: 08/02/2017] [Indexed: 12/12/2022]
Abstract
Intestinal obstruction leads to blockage of the movement of intestinal contents. After relieving the obstruction, patients might still suffer with compromised immune function and nutritional deficiency. This study aimed to evaluate the effects of Sijunzi decoction on restoring the immune function and nutritional status after relieving the obstruction. Experimental rabbits (2.5±0.2 kg) were randomly divided into normal control group, 2-day intestinal obstruction group, 2-day natural recovery group, 4-day natural recovery group, 2-day treated group, and 4-day treated group. Sijunzi decoction was given twice a day to the treated groups. The concentration of markers was analyzed to evaluate the immune function and nutritional status. The concentration of interleukin-2, immunoglobulins and complement components of the treated groups were significantly higher than the natural recovery group (P<0.05). The levels of CD4+ and CD4+/CD8+ increased then decreased in the treated groups. The levels of tumor necrosis factor-α and CD8+ were significantly lower than the natural recovery group. The level of total protein in the treated groups also increased then decreased after relieving the obstruction. The levels of albumin, prealbumin and insulin-like growth factor-1 were significantly higher in the treated groups than in the natural recovery group (P<0.05). Transferrin level in the treated groups was significantly higher than the obstruction group (P<0.05). Sijunzi decoction can lessen the inflammatory response and improve the nutrition absorption after relieving the obstruction.
Collapse
Affiliation(s)
- L Li
- Department of Gastrointestinal Surgery, Tianjin Nankai Hospital, Tianjin, China
| | - C Zou
- Department of Gastrointestinal Surgery, Tianjin Nankai Hospital, Tianjin, China
| | - Z Zhou
- Department of Gastrointestinal Surgery, Tianjin Nankai Hospital, Tianjin, China
| | - X Yu
- Department of Gastrointestinal Surgery, Tianjin Nankai Hospital, Tianjin, China
| |
Collapse
|
31
|
Shen L, Liu SJ, Zhang NS, Dai GL, Zou C, Li CY, Chen XH, Ju WZ. Sensitive and selective LC-MS/MS assay for quantitation of flutrimazole in human plasma. Eur Rev Med Pharmacol Sci 2017; 21:2964-2969. [PMID: 28682419] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE A highly sensitive liquid chromatography-tandem mass spectrometry method was developed and validated for the determination of flutrimazole in human plasma. This study was to investigate the application of sensitive and selective LC-MS/MS method for quantitation of flutrimazole in human plasma. MATERIALS AND METHODS The analysis and internal standard were extracted with ether and hexane (v:v, 1:1) followed by a rapid isocratic elution with a 0.1% formic acid/methanol (v:v, 20:80) on a C18 column (50 mm × 2.1 mm I.D.) and subsequent analysis by mass spectrometry in the multi-reaction-monitoring mode. The precursor to production transitions of m/z 279.0 → 183.1 and m/z 441.0 → 295.1 were used to measure the analyte and the internal standard. RESULTS The assay was linear over the concentration range of 0.996-99.6 ng•mL-1 for flutrimazole in human plasma. The lower limit of quantification was 0.996 ng•mL-1 and the extraction recovery was larger than 78.83% for flutrimazole. The inter- and intra-day precision of the method at three concentrations was less than 9.26%. CONCLUSIONS The LC-MS/MS method was firstly applied to quantitation of flutrimazole in human plasma.
Collapse
Affiliation(s)
- L Shen
- Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
| | | | | | | | | | | | | | | |
Collapse
|
32
|
Arenas-Ramirez N, Zou C, Popp S, Zingg D, Brannetti B, Wirth E, Calzascia T, Kovarik J, Sommer L, Zenke G, Woytschak J, Regnier CH, Katopodis A, Boyman O. Improved cancer immunotherapy by a CD25-mimobody conferring selectivity to human interleukin-2. Sci Transl Med 2016; 8:367ra166. [DOI: 10.1126/scitranslmed.aag3187] [Citation(s) in RCA: 84] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2015] [Revised: 06/08/2016] [Accepted: 09/08/2016] [Indexed: 12/31/2022]
|
33
|
Miller J, Drew L, Green O, Dukovski D, McEwan B, Villella A, Patel N, Bastos C, Cullen M, Danh H, Wachi S, Giuliano K, Longo K, Bhalla A, Qiu D, Zou C, Ivarsson M, Munoz B, Mehmet H. WS13.5 CFTR amplifiers are mutation-agnostic modulators that increase CFTR protein levels and complement other CF therapeutic modalities. J Cyst Fibros 2016. [DOI: 10.1016/s1569-1993(16)30137-0] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
34
|
Li J, Fan X, Kitova EN, Zou C, Cairo CW, Eugenio L, Ng KKS, Xiong ZJ, Privé GG, Klassen JS. Screening Glycolipids Against Proteins in Vitro Using Picodiscs and Catch-and-Release Electrospray Ionization-Mass Spectrometry. Anal Chem 2016; 88:4742-50. [PMID: 27049760 DOI: 10.1021/acs.analchem.6b00043] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
This work describes the application of the catch-and-release electrospray ionization-mass spectrometry (CaR-ESI-MS) assay, implemented using picodiscs (complexes comprised of saposin A and lipids, PDs), to screen mixtures of glycolipids (GLs) against water-soluble proteins to detect specific interactions. To demonstrate the reliability of the method, seven gangliosides (GM1, GM2, GM3, GD1a, GD1b, GD2, and GT1b) were incorporated, either individually or as a mixture, into PDs and screened against two lectins: the B subunit homopentamer of cholera toxin (CTB5) and a subfragment of toxin A from Clostridium difficile (TcdA-A2). The CaR-ESI-MS results revealed that CTB5 binds to six of the gangliosides (GM1, GM2, GM3, GD1a, GD1b, and GT1b), while TcdA-A2 binds to five of them (GM1, GM2, GM3, GD1a, and GT1b). These findings are consistent with the measured binding specificities of these proteins for ganglioside oligosaccharides. Screening mixtures of lipids extracted from porcine brain and a human epithelial cell line against CTB5 revealed binding to multiple GM1 isoforms as well as to fucosyl-GM1, which is a known ligand. Finally, a comparison of the present results with data obtained with the CaR-ESI-MS assay implemented using nanodiscs (NDs) revealed that the PDs exhibited similar or superior performance to NDs for protein-GL binding measurements.
Collapse
Affiliation(s)
- Jun Li
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| | - Xuxin Fan
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| | - Elena N Kitova
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| | - Chunxia Zou
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| | - Christopher W Cairo
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| | - Luiz Eugenio
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Biological Sciences, University of Calgary , Calgary, Alberta, Canada T2N 1N4
| | - Kenneth K S Ng
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Biological Sciences, University of Calgary , Calgary, Alberta, Canada T2N 1N4
| | - Zi Jian Xiong
- Department of Biochemistry, University of Toronto , Toronto, Ontario, Canada M5S 1A8
| | - Gilbert G Privé
- Department of Biochemistry, University of Toronto , Toronto, Ontario, Canada M5S 1A8.,Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario, Canada M5G 1L7
| | - John S Klassen
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2.,Department of Chemistry, University of Alberta , Edmonton, Alberta, Canada T6G 2G2
| |
Collapse
|
35
|
Zou C, Fu Y, Li C, Liu H, Li G, Li J, Zhang H, Wu Y, Li C. Genome-wide gene expression and DNA methylation differences in abnormally cloned and normally natural mating piglets. Anim Genet 2016; 47:436-50. [DOI: 10.1111/age.12436] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/18/2016] [Indexed: 01/24/2023]
Affiliation(s)
- C. Zou
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - Y. Fu
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - C. Li
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - H. Liu
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - G. Li
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - J. Li
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - H. Zhang
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - Y. Wu
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| | - C. Li
- Key Lab of Agriculture Animal Genetics, Breeding, and Reproduction of Ministry of Education; College of Animal Science and Technology; Huazhong Agricultural University; Wuhan 430070 People's Republic of China
| |
Collapse
|
36
|
Hu S, Ke S, Wang W, Ran H, Chen M, Zhang F, Qiu X, Jiang M, Zou C, Zhang R, Cao L, Wen Y, Fu R, Chen C. A single fas gene mutation changes lupus onset, severity, location, and molecular abnormalities in mice. Curr Mol Med 2016; 15:380-5. [PMID: 25941813 DOI: 10.2174/1566524015666150505162638] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2015] [Revised: 04/24/2015] [Accepted: 04/29/2015] [Indexed: 11/22/2022]
Abstract
Although genetic predisposition plays a major role in the progression of systemic lupus erythematosus (SLE) and its variation in symptoms, the precise relationships between genetic changes and disease status are not well understood. Here, to demonstrate the effect of a single gene mutation on disease etiology, we examined two mouse models of SLE with the same genetic background but different Fas genes. Mice with the Fas(lpr) gene developed severe SLE with renal dysfunction and inflammatory responses in the lung and kidney. By contrast, mice with the Fas(+) gene showed disease-related abnormalities in the liver and joints. Patterns of inflammatory disease markers differed across organs between the two lines of mice. Fas(lpr) mice showed greater MMP signals in the kidney and IL-11 signals in the lung than Fas(+) mice. Fas(+) mice had higher IL-11 signal intensity in the knee region and higher CXCR4 signal intensity in the liver than Fas(lpr) mice. Our results exemplify the complexity of disease and suggest the need for individualized target-specific treatment regimens. Strengths and Limitations of this Study: Fas gene is a well characterized gene in this disease. The molecular components in human disease need more clinical data.
Collapse
Affiliation(s)
| | - S Ke
- Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
37
|
McCombs JE, Zou C, Parker RB, Cairo CW, Kohler JJ. Enhanced Cross-Linking of Diazirine-Modified Sialylated Glycoproteins Enabled through Profiling of Sialidase Specificities. ACS Chem Biol 2016; 11:185-92. [PMID: 26541974 DOI: 10.1021/acschembio.5b00775] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Sialic-acid-mediated interactions play critical roles on the cell surface, providing an impetus for the development of methods to study this important monosaccharide. In particular, photo-cross-linking sialic acids incorporated onto cell surfaces have allowed covalent capture of transient interactions between sialic acids and sialic-acid-recognizing proteins via cross-linking. However, natural sialic acids also present on the cell surface compete with photo-cross-linking sialic acids in binding events, limiting cross-linking yields. In order to improve the utility of one such photo-cross-linking sialic acid, SiaDAz, we examined a number of sialidases, enzymes that remove sialic acids from glycoconjugates, to find one that would cleave natural sialic acids but remain inactive toward SiaDAz. Using this sialidase, we improved SiaDAz-mediated cross-linking of an antisialyl Lewis X antibody and of endoglin. This protocol can be applied generally to sialic-acid-mediated interactions and will facilitate identification of sialic acid binding partners.
Collapse
Affiliation(s)
- Janet E. McCombs
- Department
of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, United States
| | - Chunxia Zou
- Alberta
Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Randy B. Parker
- Department
of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, United States
| | - Christopher W. Cairo
- Alberta
Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | - Jennifer J. Kohler
- Department
of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, Texas 75390-9038, United States
| |
Collapse
|
38
|
Zeng YQ, Liu XS, Wu S, Zou C, Xie Q, Xu SM, Jin XW, Li W, Zhou A, Dai Z. Kaempferol Promotes Transplant Tolerance by Sustaining CD4+FoxP3+ Regulatory T Cells in the Presence of Calcineurin Inhibitor. Am J Transplant 2015; 15:1782-92. [PMID: 25808405 DOI: 10.1111/ajt.13261] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2014] [Revised: 02/01/2015] [Accepted: 02/05/2015] [Indexed: 01/25/2023]
Abstract
Calcineurin inhibitor cyclosporine is widely used as an immunosuppressant in clinic. However, mounting evidence has shown that cyclosporine hinders tolerance induction by dampening Tregs. Therefore, it is of paramount importance to overcome this pitfall. Kaempferol was reported to inhibit DC function. Here, we found that kaempferol delayed islet allograft rejection. Combination of kaempferol and low-dose, but not high-dose, of cyclosporine induced allograft tolerance in majority of recipient mice. Although kaempferol plus either dose of cyclosporine largely abrogated proliferation of graft-infiltrating T cells and their CTL activity, both proliferation and CTL activity in mice treated with kaempferol plus low-dose, but not high-dose, cyclosporine reemerged rapidly upon treatment withdrawal. Kaempferol increased CD4+FoxP3+ Tregs both in transplanted mice and in vitro, likely by suppressing DC maturation and their IL-6 expression. Reduction in Tregs by low dose of cyclosporine was reversed by kaempferol. Kaempferol-induced Tregs exhibited both allospecific and non-allospecific suppression. Administering IL-6 abrogated allograft tolerance induced by kaempferol and cyclosporine via diminishing CD4+FoxP3+ Tregs. Thus, for the first time, we demonstrated that kaempferol promotes transplant tolerance in the presence of low dose of cyclosporine, which allows for sufficient Treg generation while minimizing side effects, resulting in much-needed synergy between kaempferol and cyclosporine.
Collapse
Affiliation(s)
- Y Q Zeng
- Department of Nephrology, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - X S Liu
- Department of Nephrology, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - S Wu
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - C Zou
- Department of Nephrology, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - Q Xie
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - S M Xu
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - X W Jin
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - W Li
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| | - A Zhou
- The Cardiovascular Research Center, Warren Alpert Medical School of Brown University, Providence, RI
| | - Z Dai
- Center for Regenerative and Translational Medicine, the Second Clinical College, Guangzhou University of Chinese Medicine, and Guangdong Provincial Academy of Chinese Medical Sciences, Guangzhou, Guangdong, P. R. China
| |
Collapse
|
39
|
Song H, Deng B, Zou C, Huai W, Zhao R, Zhao W. GSK3β negatively regulates LPS-induced osteopontin expression via inhibiting its transcription. Scand J Immunol 2015; 81:186-91. [PMID: 25565601 DOI: 10.1111/sji.12268] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2014] [Accepted: 12/03/2014] [Indexed: 01/23/2023]
Abstract
Osteopontin (OPN) is expressed by a variety of immune cells and is critical for both innate and adaptive immune responses. The expression status of OPN might be tightly regulated to maintain immune homeostasis. However, the mechanisms by which OPN is negatively regulated in LPS-stimulated macrophages remain largely unknown. In this study, we showed that glycogen synthase kinase 3β (GSK3β) inhibitors - SB216763, LiCl and azakenpaullone - enhanced LPS-induced OPN expression in mouse peritoneal macrophages. GSK3β knock-down had the similar effects. Furthermore, we found that GSK3β inhibitors and GSK3β knock-down both increased the activity of OPN promoter in LPS-stimulated macrophages. GSK3β inhibitor-mediated enhancement of LPS-induced OPN promoter activity was abrogated in GSK3β siRNA-treated macrophages. Therefore, we identified GSK3β as a negative regulator of OPN expression and suggest GSK3β as a potential therapeutic target for the intervention of diseases with uncontrolled OPN production.
Collapse
Affiliation(s)
- H Song
- Department of Immunology, Shandong University School of Medicine, Jinan, Shandong, China
| | | | | | | | | | | |
Collapse
|
40
|
Leney AC, Rezaei Darestani R, Li J, Nikjah S, Kitova EN, Zou C, Cairo CW, Xiong ZJ, Privé GG, Klassen JS. Picodiscs for facile protein-glycolipid interaction analysis. Anal Chem 2015; 87:4402-8. [PMID: 25803566 DOI: 10.1021/acs.analchem.5b00170] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Protein interactions with glycolipids are implicated in diverse cellular processes. However, the study of protein-glycolipid complexes remains a significant experimental challenge. Here, we describe a powerful new assay that combines electrospray ionization mass spectrometry (ESI-MS) and picodiscs, which are composed of human sphingolipid activator protein saposin A and a small number of phospholipids, to display glycolipids in a lipid environment for protein-glycolipid interaction studies in aqueous solution. Time-resolved measurements of enzyme catalyzed hydrolysis of glycolipid substrates and the detection of low, moderate, and high affinity protein-glycolipid interactions serve to demonstrate the reliability and versatility of the assay.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | - Zi Jian Xiong
- §Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada M5S 1A8
| | - Gilbert G Privé
- §Department of Biochemistry, University of Toronto, Toronto, Ontario, Canada M5S 1A8.,∥Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada M5G 1L7
| | | |
Collapse
|
41
|
Abstract
The present study investigated the hepatoprotective role of selenium during alloxan-induced diabetes in rats. Male Wistar rats were divided into four groups, namely, normal control, selenium treated, diabetic, and selenium-treated diabetic. Diabetes was induced in the animals by injecting alloxan intraperitoneally at a dose rate of 150 mg/kg body weight. Selenium in the form of sodium selenite was supplemented to rats at a dose level of 1 ppm in drinking water, ad libitum for two time durations of 2 and 4 weeks. The effects of different treatments were studied on various parameters in rat liver, which included serum glucose levels, serum insulin levels, alkaline phosphatase (ALP), aspartate aminotransferase (AST), alanine aminotransferase (ALT), lipid peroxidation (LPO), glutathione reduced (GSH), oxidized glutathione (GSSG), total glutathione (TG), superoxide dismutase (SOD), catalase (CAT), glutathione reductase, glutathione peroxidase, metallothionein (MT), and histoarchitecture. A significant increase in the serum glucose levels, LPO levels, and in enzyme activities of ALP, ALT, and AST was observed in diabetic rats which, however, got decreased significantly upon supplementation with selenium. On the contrary, decreased enzyme activities of GSSG, SOD, and CAT and depressed levels of GSH as well as serum insulin levels were observed in diabetic rats which got improved following selenium supplementation. Interestingly, MT levels were increased both in diabetic and selenium-treated diabetic rats. Further, marked alterations in histoarchitecture were seen in diabetic rats with the prominent features being congestion in sinusoids, lipid accumulation, and centrilobular hepatocyte degeneration. However, selenium treatment to diabetic rats showed overall improvement in the hepatic histoarchitecture.
Collapse
Affiliation(s)
- C Zou
- Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical College, Southeast University, Jiangsu, China Xuzhou Institute of Medical Sciences, Xuzhou Institute of Diabetes, Xuzhou, Jiangsu, China
| | - Q Qiu
- Xuzhou Medical College, Xuzhou, Jiangsu, China
| | - H Chen
- Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical College, Southeast University, Jiangsu, China Xuzhou Institute of Medical Sciences, Xuzhou Institute of Diabetes, Xuzhou, Jiangsu, China
| | - L Dou
- Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical College, Southeast University, Jiangsu, China Xuzhou Institute of Medical Sciences, Xuzhou Institute of Diabetes, Xuzhou, Jiangsu, China
| | - J Liang
- Department of Endocrinology, Xuzhou Central Hospital, Xuzhou Clinical School of Xuzhou Medical College, Southeast University, Jiangsu, China Xuzhou Institute of Medical Sciences, Xuzhou Institute of Diabetes, Xuzhou, Jiangsu, China Xuzhou Medical College, Xuzhou, Jiangsu, China
| |
Collapse
|
42
|
Blazquez-Llorca L, Hummel E, Zimmerman H, Zou C, Burgold S, Rietdorf J, Herms J. Correlation of two-photon in vivo imaging and FIB/SEM microscopy. J Microsc 2015; 259:129-136. [PMID: 25786682 PMCID: PMC4672704 DOI: 10.1111/jmi.12231] [Citation(s) in RCA: 38] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2014] [Accepted: 01/28/2015] [Indexed: 11/29/2022]
Abstract
Advances in the understanding of brain functions are closely linked to the technical developments in microscopy. In this study, we describe a correlative microscopy technique that offers a possibility of combining two-photon in vivo imaging with focus ion beam/scanning electron microscope (FIB/SEM) techniques. Long-term two-photon in vivo imaging allows the visualization of functional interactions within the brain of a living organism over the time, and therefore, is emerging as a new tool for studying the dynamics of neurodegenerative diseases, such as Alzheimer’s disease. However, light microscopy has important limitations in revealing alterations occurring at the synaptic level and when this is required, electron microscopy is mandatory. FIB/SEM microscopy is a novel tool for three-dimensional high-resolution reconstructions, since it acquires automated serial images at ultrastructural level. Using FIB/SEM imaging, we observed, at 10 nm isotropic resolution, the same dendrites that were imaged in vivo over 9 days. Thus, we analyzed their ultrastructure and monitored the dynamics of the neuropil around them. We found that stable spines (present during the 9 days of imaging) formed typical asymmetric contacts with axons, whereas transient spines (present only during one day of imaging) did not form a synaptic contact. Our data suggest that the morphological classification that was assigned to a dendritic spine according to the in vivo images did not fit with its ultrastructural morphology. The correlative technique described herein is likely to open opportunities for unravelling the earlier unrecognized complexity of the nervous system.
Collapse
Affiliation(s)
- L Blazquez-Llorca
- Center for Neuropathology and Prion Research (ZNP) and German Center for Neurodegenerative Diseases (DZNE) - site Munich, Ludwig-Maximilians-University Munich, Munich, Germany
| | - E Hummel
- Carl Zeiss Microscopy, Munich, Germany
| | | | - C Zou
- Center for Neuropathology and Prion Research (ZNP) and German Center for Neurodegenerative Diseases (DZNE) - site Munich, Ludwig-Maximilians-University Munich, Munich, Germany
| | - S Burgold
- Center for Neuropathology and Prion Research (ZNP) and German Center for Neurodegenerative Diseases (DZNE) - site Munich, Ludwig-Maximilians-University Munich, Munich, Germany
| | | | - J Herms
- Center for Neuropathology and Prion Research (ZNP) and German Center for Neurodegenerative Diseases (DZNE) - site Munich, Ludwig-Maximilians-University Munich, Munich, Germany.,Munich Cluster of Systems Neurology (SyNergy), Ludwig-Maximilians-University, Munich, Munich, Germany
| |
Collapse
|
43
|
Liu Y, Lear T, Zhao Y, Zhao J, Zou C, Chen BB, Mallampalli RK. F-box protein Fbxl18 mediates polyubiquitylation and proteasomal degradation of the pro-apoptotic SCF subunit Fbxl7. Cell Death Dis 2015; 6:e1630. [PMID: 25654763 PMCID: PMC4669792 DOI: 10.1038/cddis.2014.585] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2014] [Revised: 11/11/2014] [Accepted: 11/20/2014] [Indexed: 01/25/2023]
Abstract
Fbxl7, a subunit of the SCF (Skp-Cul1-F-box protein) complex induces mitotic arrest in cells; however, molecular factors that control its cellular abundance remain largely unknown. Here, we identified that an orphan F-box protein, Fbxl18, targets Fbxl7 for its polyubiquitylation and proteasomal degradation. Lys 109 within Fbxl7 is an essential acceptor site for ubiquitin conjugation by Fbxl18. An FQ motif within Fbxl7 serves as a molecular recognition site for Fbxl18 interaction. Ectopically expressed Fbxl7 induces apoptosis in Hela cells, an effect profoundly accentuated after cellular depletion of Fbxl18 protein or expression of Fbxl7 plasmids encoding mutations at either Lys 109 or within the FQ motif. Ectopic expression of Fbxl18 plasmid-limited apoptosis caused by overexpressed Fbxl7 plasmid. Thus, Fbxl18 regulates apoptosis by mediating ubiquitin-dependent proteasomal degradation of the pro-apoptotic protein Fbxl7 that may impact cellular processes involved in cell cycle progression.
Collapse
Affiliation(s)
- Y Liu
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - T Lear
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - Y Zhao
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - J Zhao
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - C Zou
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - B B Chen
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
| | - R K Mallampalli
- Department of Medicine, the Acute Lung Injury Center of Excellence, University of Pittsburgh, Pittsburgh, PA, USA
- Medical Specialty Service Line, Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA, USA
| |
Collapse
|
44
|
Cao L, Chen S, Zou C, Ding X, Gao L, Liao Z, Liu G, Malmstrom TK, Morley JE, Flaherty JH, An Y, Dong B. A pilot study of the SARC-F scale on screening sarcopenia and physical disability in the Chinese older people. J Nutr Health Aging 2014; 18:277-83. [PMID: 24626755 DOI: 10.1007/s12603-013-0410-3] [Citation(s) in RCA: 98] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Abstract
INTRODUCTION The SARC-F scale is a newly developed tool to diagnose sarcopenia and obviate the need for measurement of muscle mass. SARC-F ≥ 4 is defined as sarcopenia. The questions of SARC-F cover physical functions targeting sarcopenia or initial presentation for sarcopenia. The aim of the study is to explore the application of SARC-F in the Chinese people. METHODS Two hundred thirty Chinese people over 65 years old were assessed by the SARC-F scale, PSMS, Lawton IADL and the shortened version of the falls efficacy scale-international(the short FES-I). Hospitalization was investigated. Physical performance and strength were measured. The association of SARC-F with other scales or tests was analyzed. RESULTS Poor physical performance and grip strength were associated with SARC-F ≥ 4 independently (P<0.005). The κ value for agreement of SARC-F ≥ 4 and cutoff points of tests were 0.391 to 0.635. The short FES-I were correlated to SARC-F scores (Spearman's coefficient 0.692). Poor PSMS and Lawton IADL scores were associated with SARC-F ≥ 4(P=0.000) and SARC-F ≥ 4 was associated with hospitalization in the past 2 years (P=0.000). CONCLUSION The SARC-F scale can identify old Chinese people with impaired physical function who may suffered from sarcopenia. SARC-F judgment reflects fear of falling, indicates the hospitalization events and is associated with ability of daily life. Thus, SARC-F may be a simple and useful tool for screening individuals with impaired physical function. Further studies on SARC-F in Chinese people would be worthy.
Collapse
Affiliation(s)
- L Cao
- Birong Dong, No. 37 Guoxuexiang, Wuhou District, Chengdu, China, 610041, , FAX: 028-85422321
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Leymarie N, Griffin PJ, Jonscher K, Kolarich D, Orlando R, McComb M, Zaia J, Aguilan J, Alley WR, Altmann F, Ball LE, Basumallick L, Bazemore-Walker CR, Behnken H, Blank MA, Brown KJ, Bunz SC, Cairo CW, Cipollo JF, Daneshfar R, Desaire H, Drake RR, Go EP, Goldman R, Gruber C, Halim A, Hathout Y, Hensbergen PJ, Horn DM, Hurum D, Jabs W, Larson G, Ly M, Mann BF, Marx K, Mechref Y, Meyer B, Möginger U, Neusüβ C, Nilsson J, Novotny MV, Nyalwidhe JO, Packer NH, Pompach P, Reiz B, Resemann A, Rohrer JS, Ruthenbeck A, Sanda M, Schulz JM, Schweiger-Hufnagel U, Sihlbom C, Song E, Staples GO, Suckau D, Tang H, Thaysen-Andersen M, Viner RI, An Y, Valmu L, Wada Y, Watson M, Windwarder M, Whittal R, Wuhrer M, Zhu Y, Zou C. Interlaboratory study on differential analysis of protein glycosylation by mass spectrometry: the ABRF glycoprotein research multi-institutional study 2012. Mol Cell Proteomics 2013; 12:2935-51. [PMID: 23764502 PMCID: PMC3790302 DOI: 10.1074/mcp.m113.030643] [Citation(s) in RCA: 91] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2013] [Revised: 06/11/2013] [Indexed: 11/06/2022] Open
Abstract
One of the principal goals of glycoprotein research is to correlate glycan structure and function. Such correlation is necessary in order for one to understand the mechanisms whereby glycoprotein structure elaborates the functions of myriad proteins. The accurate comparison of glycoforms and quantification of glycosites are essential steps in this direction. Mass spectrometry has emerged as a powerful analytical technique in the field of glycoprotein characterization. Its sensitivity, high dynamic range, and mass accuracy provide both quantitative and sequence/structural information. As part of the 2012 ABRF Glycoprotein Research Group study, we explored the use of mass spectrometry and ancillary methodologies to characterize the glycoforms of two sources of human prostate specific antigen (PSA). PSA is used as a tumor marker for prostate cancer, with increasing blood levels used to distinguish between normal and cancer states. The glycans on PSA are believed to be biantennary N-linked, and it has been observed that prostate cancer tissues and cell lines contain more antennae than their benign counterparts. Thus, the ability to quantify differences in glycosylation associated with cancer has the potential to positively impact the use of PSA as a biomarker. We studied standard peptide-based proteomics/glycomics methodologies, including LC-MS/MS for peptide/glycopeptide sequencing and label-free approaches for differential quantification. We performed an interlaboratory study to determine the ability of different laboratories to correctly characterize the differences between glycoforms from two different sources using mass spectrometry methods. We used clustering analysis and ancillary statistical data treatment on the data sets submitted by participating laboratories to obtain a consensus of the glycoforms and abundances. The results demonstrate the relative strengths and weaknesses of top-down glycoproteomics, bottom-up glycoproteomics, and glycomics methods.
Collapse
Affiliation(s)
- Nancy Leymarie
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts 02118
| | - Paula J. Griffin
- §Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts 02118
| | - Karen Jonscher
- ¶Department of Anesthesiology University of Colorado, Aurora, Colorado 80045
| | - Daniel Kolarich
- ‖Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, 14476, Germany
| | - Ron Orlando
- **Complex Carbohydrates Research Center, University of Georgia, Athens, Georgia, 30602
| | - Mark McComb
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts 02118
| | - Joseph Zaia
- From the ‡Center for Biomedical Mass Spectrometry, Boston University School of Medicine, Boston, Massachusetts 02118
| | - Jennifer Aguilan
- §§Laboratory for Macromolecular Analysis and Proteomics Facility, Albert Einstein College of Medicine, Bronx, New York 10461
| | - William R. Alley
- ¶¶Department of Chemistry, Indiana University, Bloomington, Indiana 47405
| | - Friederich Altmann
- ‖‖Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, A-1180, Austria
| | - Lauren E. Ball
- MUSC Proteomic Center, Medical University of South Carolina, Charleston, South Carolina 29425
| | - Lipika Basumallick
- Applications Development, Dionex Products, Thermo Fisher Scientific, Sunnyvale, California 94085
| | | | - Henning Behnken
- Organic Chemistry, University of Hamburg, Hamburg, 20146, Germany
| | | | - Kristy J. Brown
- Center for Genetic Medicine, Children's National Medical Center, Washington, D.C. 20310
| | | | - Christopher W. Cairo
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, Canada
- Alberta Glycomics Centre, University of Alberta, Edmonton, T6G 2G2, Canada
| | - John F. Cipollo
- Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20993
| | - Rambod Daneshfar
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, Canada
- Alberta Glycomics Centre, University of Alberta, Edmonton, T6G 2G2, Canada
| | | | - Richard R. Drake
- MUSC Proteomic Center, Medical University of South Carolina, Charleston, South Carolina 29425
| | - Eden P. Go
- University of Kansas, Lawrence, Kansas 66045
| | - Radoslav Goldman
- Department of Oncology, Georgetown University, Washington, D.C. 20007
| | - Clemens Gruber
- ‖‖Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, A-1180, Austria
| | - Adnan Halim
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 41345, Sweden
| | - Yetrib Hathout
- Center for Genetic Medicine, Children's National Medical Center, Washington, D.C. 20310
| | - Paul J. Hensbergen
- Biomolecular Mass Spectrometry Unit, Leiden University Medical Center, Leiden, 233ZA, The Netherlands
| | - David M. Horn
- Thermo Fisher Scientific, San Jose, California 95134
| | - Deanna Hurum
- Applications Development, Dionex Products, Thermo Fisher Scientific, Sunnyvale, California 94085
| | | | - Göran Larson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 41345, Sweden
| | - Mellisa Ly
- Agilent Laboratories, Agilent Technologies, Santa Clara, California 95051
| | - Benjamin F. Mann
- ¶¶Department of Chemistry, Indiana University, Bloomington, Indiana 47405
| | | | - Yehia Mechref
- Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409
| | - Bernd Meyer
- Organic Chemistry, University of Hamburg, Hamburg, 20146, Germany
| | - Uwe Möginger
- ‖Max Planck Institute of Colloids and Interfaces, 14424 Potsdam, 14476, Germany
| | | | - Jonas Nilsson
- Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, 41345, Sweden
| | - Milos V. Novotny
- ¶¶Department of Chemistry, Indiana University, Bloomington, Indiana 47405
| | - Julius O. Nyalwidhe
- Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr Cancer Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507
| | - Nicolle H. Packer
- Biomolecular Frontiers Research Centre, Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, NSW 2109, Australia
| | - Petr Pompach
- Department of Oncology, Georgetown University, Washington, D.C. 20007
| | - Bela Reiz
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, Canada
| | | | - Jeffrey S. Rohrer
- Applications Development, Dionex Products, Thermo Fisher Scientific, Sunnyvale, California 94085
| | | | - Miloslav Sanda
- Department of Oncology, Georgetown University, Washington, D.C. 20007
| | - Jan Mirco Schulz
- Organic Chemistry, University of Hamburg, Hamburg, 20146, Germany
| | | | - Carina Sihlbom
- Proteomics Core Facility, Gothenburg University, Gothenburg, 413 90, Sweden
| | - Ehwang Song
- Department of Chemistry and Biochemistry, Texas Tech University, Lubbock, Texas 79409
| | - Gregory O. Staples
- Agilent Laboratories, Agilent Technologies, Santa Clara, California 95051
| | | | - Haixu Tang
- School of informatics, Indiana University, Bloomington, Indiana 47405
| | - Morten Thaysen-Andersen
- Biomolecular Frontiers Research Centre, Department of Chemistry and Biomolecular Sciences, Macquarie University, Sydney, NSW 2109, Australia
| | - Rosa I. Viner
- Thermo Fisher Scientific, San Jose, California 95134
| | - Yanming An
- Center for Biologics Evaluation and Research, Food and Drug Administration, Bethesda, Maryland 20993
| | - Leena Valmu
- Finnish Red Cross Blood Service, Helsinki, 00310, Finland
| | - Yoshinao Wada
- Research Institute, Osaka Medical Center for Maternal and Child Health, Izumi, Osaka, 594–1101, Japan
| | - Megan Watson
- Department of Microbiology and Molecular Cell Biology, Leroy T. Canoles Jr Cancer Research Center, Eastern Virginia Medical School, Norfolk, Virginia 23507
| | - Markus Windwarder
- ‖‖Department of Chemistry, University of Natural Resources and Life Sciences, Vienna, A-1180, Austria
| | - Randy Whittal
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, Canada
| | - Manfred Wuhrer
- Biomolecular Mass Spectrometry Unit, Leiden University Medical Center, Leiden, 233ZA, The Netherlands
| | - Yiying Zhu
- Department of Chemistry, Brown University, Providence, Rhode Island 02912
| | - Chunxia Zou
- Department of Chemistry, University of Alberta, Edmonton, T6G 2G2, Canada
- Alberta Glycomics Centre, University of Alberta, Edmonton, T6G 2G2, Canada
| |
Collapse
|
46
|
Ke S, Wang W, Qiu X, Zhang F, Yustein JT, Cameron AG, Zhang S, Yu D, Zou C, Gao X, Lin J, Yallampalli S, Li M. Multiple target-specific molecular agents for detection and image analysis of breast cancer characteristics in mice. Curr Mol Med 2013; 13:446-58. [PMID: 23331017 PMCID: PMC3636521 DOI: 10.2174/1566524011313030014] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2012] [Revised: 10/12/2012] [Accepted: 10/15/2012] [Indexed: 01/25/2023]
Abstract
Breast cancer is a heterogenetic tumor at the cellular level with multiple factors and components. The inconsistent expression of molecular markers during disease progression reduces the accuracy of diagnosis and efficacy of target-specific therapy. Single target-specific imaging agents can only provide limited tumor information at one time point. In contrast, multiple target-specific imaging agents can increase the accuracy of diagnosis. The aim of this study was to demonstrate the ability of multi-agent imaging to discriminate such differences in single tumor. Mice bearing human cancer cell xenografts were tested to determine individual differences under optimal experimental conditions. Neovasculature agent (RGD peptide), tumor stromal agent (matrix metalloproteinase), and tumor cell markers (epidermal growth factor, Her-2, interleukin 11) imaging agents were labeled with reporters. 18F-Fluorodeoxyglucose was used to evaluate the tumor glucose status. Optical, X-ray, positron emission tomography, and computer tomography imaging modalities were used to determine tumor characteristics. Tumor size and imaging data demonstrated that individual differences exist under optimal experimental conditions. The target-specific agents used in the study bind to human breast cancer cell lines in vitro and xenografts in vivo. The pattern of binding corresponds to that of tumor markers. Multi-agent imaging had complementary effects in tumor detection. Multiple noninvasive imaging agents and modalities are complementary in the interrogation of unique biological information from each individual tumor. Such multi-agent approaches provide methods to study several disease components simultaneously. In addition, the imaging results provide information on disease status at the molecular level.
Collapse
Affiliation(s)
- S Ke
- Department of Radiology, Baylor College of Medicine, One Baylor Plaza, MS: BCM360, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
47
|
Abstract
The glycan of specific proteins can dictate the response of cells to stimuli, and thus their phenotype. We describe a chemical strategy to modify the cellular glycoform of T cells, which resulted in a modified cellular response. Our data indicate that chemical modification of the phosphatase CD45 is responsible for the observed differences in response to receptor cross-linking. By increasing the content of galactose epitopes in the glycocalyx of a lymphoma cell line, we were able to increase the response of the cell to lectin stimulation through the glycoprotein receptor, CD45. The method described here exploits metabolic labeling of a cell to reprogram the cellular response to external stimuli though changes in the number of lectin binding sites on the cell surface.
Collapse
Affiliation(s)
- Chunxia Zou
- Alberta Glycomics Centre, Department of Chemistry, University of Alberta, Edmonton, Alberta T6G 2G2, Canada
| | | | | | | |
Collapse
|
48
|
An T, Zhang Y, Huang Y, Zhang R, Yin S, Guo X, Wang Y, Zou C, Wei B, Lv R, Zhou Q, Zhang J. Neuregulin-1 protects against doxorubicin-induced apoptosis in cardiomyocytes through an Akt-dependent pathway. Physiol Res 2013; 62:379-85. [PMID: 23590603 DOI: 10.33549/physiolres.932516] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
In previous studies, it has been shown that recombinant human neuregulin-1(rhNRG-1) is capable of improving the survival rate in animal models of doxorubicin (DOX)-induced cardiomyopathy; however, the underlying mechanism of this phenomenon remains unknown. In this study, the role of rhNRG-1 in attenuating doxorubicin-induce apoptosis is confirmed. Neonatal rat ventricular myocytes (NRVMs) were subjected to various treatments, in order to both induce apoptosis and determine the effects of rhNRG-1 on the process. Activation of apoptosis was determined by observing increases in the protein levels of classic apoptosis markers (including cleaved caspase-3, cytochrome c, Bcl-2, BAX and terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick-end labeling (TUNEL) staining). The activation of Akt was detected by means of western blot analysis. The study results showed that doxorubicin increased the number of TUNEL positive cells, as well as the protein levels of cleaved caspase-3 and cytochrome c, and reduced the ratio of Bcl-2/Bax. However, all of these effects were markedly antagonized by pretreament with rhNRG-1. It was then further demonstrated that the effects of rhNRG-1 could be blocked by the phosphoinositole-3-kinase inhibitor LY294002, indicating the involvement of the Akt process in mediating the process. RhNRG-1 is a potent inhibitor of doxorubicin-induced apoptosis, which acts through the PI3K-Akt pathway. RhNRG-1 is a novel therapeutic drug which may be effective in preventing further damage from occurring in DOX-induced damaged myocardium.
Collapse
Affiliation(s)
- T An
- Heart Failure Center, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
49
|
Ke S, Wang W, Qiu X, Zhang F, T. Yustein J, G. Cameron A, Zhang S, Yu D, Zou C, Gao X, Lin J, Yallampalli S, Li M. Multiple Target-Specific Molecular Agents for Detection and Image Analysis of Breast Cancer Characteristics in Mice. Curr Mol Med 2013. [DOI: 10.2174/156652413805076849] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
50
|
Ke S, Zhang F, Wang W, Qiu X, Lin J, Cameron AG, Zou C, Gao X, Zou C, Zhu VF, Li M. Multiple target-specific molecular imaging agents detect liver cancer in a preclinical model. Curr Mol Med 2013; 12:944-51. [PMID: 22779431 PMCID: PMC3428706 DOI: 10.2174/156652412802480952] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/05/2012] [Revised: 04/27/2012] [Accepted: 05/06/2012] [Indexed: 12/21/2022]
Abstract
Liver cancer is the fifth most common cause of cancer deaths worldwide. Noninvasive diagnosis is difficult and the disease heterogeneity reduces the accuracy of pathological assays. Improvement in diagnostic imaging of specific molecular disease markers has provided hope for accurate and early noninvasive detection of liver cancer. However, all current imaging technologies, including ultrasonography, computed tomography (CT), positron emission tomography (PET), and magnetic resonance imaging, are not specific targets for detection of liver cancer. The aim of this study was to test the feasibility of injecting a cocktail of specific molecular imaging agents to noninvasively image liver cancer. The target-specific cocktail contained agents for imaging the neovasculature (RGD peptide), matrix metalloproteinase (MMP), and glucose transport (18F-fluorodeoxyglucose [18F-FDG]). Imaging studies were performed in liver cancer cells and xenograft models. The distribution of MMP at the intracellular level was imaged by confocal microscopy. RGD, MMP, and 18F-FDG were imaged on tumor-bearing mice using PET, CT, X-ray, and multi-wavelength optical imaging modalities. Image data demonstrated that each agent bound to a specific disease target component. The same liver cancer xenograft contained multiple disease markers. Those disease markers were heterogenetically distributed in the same tumor nodule. The molecular imaging agents had different distributions in the whole body and inside the tumor nodule. All target-specific agents yielded high tumor-to-background ratios after injection. In conclusion, target-specific molecular imaging agents can be used to study liver cancer in vitro and in vivo. Noninvasive multimodal/multi-target-specific molecular imaging agents could provide tools to simultaneously study multiple liver cancer components.
Collapse
Affiliation(s)
- S Ke
- Department of Radiology, Baylor College of Medicine, One Baylor Plaza, MS 360, Houston, Texas 77030, USA.
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|